AU2020277027A1 - Compounds for treating huntington's disease - Google Patents
Compounds for treating huntington's disease Download PDFInfo
- Publication number
- AU2020277027A1 AU2020277027A1 AU2020277027A AU2020277027A AU2020277027A1 AU 2020277027 A1 AU2020277027 A1 AU 2020277027A1 AU 2020277027 A AU2020277027 A AU 2020277027A AU 2020277027 A AU2020277027 A AU 2020277027A AU 2020277027 A1 AU2020277027 A1 AU 2020277027A1
- Authority
- AU
- Australia
- Prior art keywords
- pyridin
- pyridazin
- fluoro
- oxy
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 507
- 208000023105 Huntington disease Diseases 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- -1 piperidin-1-olate-yl Chemical group 0.000 claims description 5044
- 125000001424 substituent group Chemical group 0.000 claims description 280
- 125000000623 heterocyclic group Chemical group 0.000 claims description 265
- 125000001072 heteroaryl group Chemical group 0.000 claims description 183
- 125000004076 pyridyl group Chemical group 0.000 claims description 104
- 229910052760 oxygen Inorganic materials 0.000 claims description 88
- 125000005842 heteroatom Chemical group 0.000 claims description 86
- 125000002950 monocyclic group Chemical group 0.000 claims description 86
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 80
- 125000004193 piperazinyl group Chemical group 0.000 claims description 80
- 125000003386 piperidinyl group Chemical group 0.000 claims description 77
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 74
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 64
- 125000002619 bicyclic group Chemical group 0.000 claims description 48
- 229920006395 saturated elastomer Polymers 0.000 claims description 48
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 42
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 41
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 36
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 35
- 229910052736 halogen Inorganic materials 0.000 claims description 33
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 31
- 125000005955 1H-indazolyl group Chemical group 0.000 claims description 31
- 125000002883 imidazolyl group Chemical group 0.000 claims description 31
- 125000002971 oxazolyl group Chemical group 0.000 claims description 31
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 29
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 19
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 3
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 claims 26
- FHZOTUIUSLSFDU-LJLRIERRSA-N CC1(C[C@H]([C@H](C(N1)(C)C)F)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.Cl Chemical compound CC1(C[C@H]([C@H](C(N1)(C)C)F)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.Cl FHZOTUIUSLSFDU-LJLRIERRSA-N 0.000 claims 6
- PZJIPXYCKROSLJ-OKILXGFUSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C PZJIPXYCKROSLJ-OKILXGFUSA-N 0.000 claims 6
- DECYQCLCPJBWDO-CRAIPNDOSA-N FC1=C(C=NN1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O Chemical compound FC1=C(C=NN1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O DECYQCLCPJBWDO-CRAIPNDOSA-N 0.000 claims 6
- FVYOVBZNDVIMHP-LPHOPBHVSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)(C)C)(C)C FVYOVBZNDVIMHP-LPHOPBHVSA-N 0.000 claims 6
- FVYOVBZNDVIMHP-VQIMIIECSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)(C)C)(C)C FVYOVBZNDVIMHP-VQIMIIECSA-N 0.000 claims 6
- YUBMMGFJTJWQAK-UHFFFAOYSA-N CC1(NC2(CC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1F)C Chemical compound CC1(NC2(CC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1F)C YUBMMGFJTJWQAK-UHFFFAOYSA-N 0.000 claims 4
- BJXSAVYWDGJREZ-REWPJTCUSA-N CC=1N=C2N(N=C(C=C2C)C=2C=C(C(=NC=2)C=2N=NC(=CC=2)O[C@@H]2[C@@H](C(NC(C2)(C)C)(C)C)F)O)C=1 Chemical compound CC=1N=C2N(N=C(C=C2C)C=2C=C(C(=NC=2)C=2N=NC(=CC=2)O[C@@H]2[C@@H](C(NC(C2)(C)C)(C)C)F)O)C=1 BJXSAVYWDGJREZ-REWPJTCUSA-N 0.000 claims 4
- BJXSAVYWDGJREZ-NFBKMPQASA-N CC=1N=C2N(N=C(C=C2C)C=2C=C(C(=NC=2)C=2N=NC(=CC=2)O[C@H]2[C@H](C(NC(C2)(C)C)(C)C)F)O)C=1 Chemical compound CC=1N=C2N(N=C(C=C2C)C=2C=C(C(=NC=2)C=2N=NC(=CC=2)O[C@H]2[C@H](C(NC(C2)(C)C)(C)C)F)O)C=1 BJXSAVYWDGJREZ-NFBKMPQASA-N 0.000 claims 4
- UCSROBWHQSVAOQ-OKILXGFUSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC(=NC=C1)OC)O Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC(=NC=C1)OC)O UCSROBWHQSVAOQ-OKILXGFUSA-N 0.000 claims 4
- OUTUIFKYJKSYSG-GASCZTMLSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC2=CN(N=C2C(=C1)C#N)C)O Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC2=CN(N=C2C(=C1)C#N)C)O OUTUIFKYJKSYSG-GASCZTMLSA-N 0.000 claims 4
- DTMSVMZVVXXPAM-GASCZTMLSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)OC)C Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)OC)C DTMSVMZVVXXPAM-GASCZTMLSA-N 0.000 claims 4
- XSHDKJPGXQUPEX-GASCZTMLSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C=C1)C Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C=C1)C XSHDKJPGXQUPEX-GASCZTMLSA-N 0.000 claims 4
- RAMMEHJPVXPCQF-OKILXGFUSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CNN=C2C=C1 Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CNN=C2C=C1 RAMMEHJPVXPCQF-OKILXGFUSA-N 0.000 claims 4
- QEXQAIHXZVAACI-GASCZTMLSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=C2C=NN(C2=CC=1)C Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=C2C=NN(C2=CC=1)C QEXQAIHXZVAACI-GASCZTMLSA-N 0.000 claims 4
- WFRKIVSHIORDSH-GASCZTMLSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)C=C(N=2)C Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)C=C(N=2)C WFRKIVSHIORDSH-GASCZTMLSA-N 0.000 claims 4
- RHTPUDHZKVRMRP-OKILXGFUSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)N=C(N=2)C Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)N=C(N=2)C RHTPUDHZKVRMRP-OKILXGFUSA-N 0.000 claims 4
- DIIFYEYNCPMKSM-OKILXGFUSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)N=CN=2 Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)N=CN=2 DIIFYEYNCPMKSM-OKILXGFUSA-N 0.000 claims 4
- NSMXOOPWAIPZRE-OKILXGFUSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NC=2N(C=1)C=C(N=2)C Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NC=2N(C=1)C=C(N=2)C NSMXOOPWAIPZRE-OKILXGFUSA-N 0.000 claims 4
- GOQGOVXRCDHTHD-TXEJJXNPSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 GOQGOVXRCDHTHD-TXEJJXNPSA-N 0.000 claims 4
- AIUZKOVLLPBLMY-ZTXBFCOASA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)\C=C\C=1C=NN(C=1)C Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)\C=C\C=1C=NN(C=1)C AIUZKOVLLPBLMY-ZTXBFCOASA-N 0.000 claims 4
- UBZQRNCSIRFQIO-YZQYOJQGSA-N C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)/C=C/C4=CN(N=C4)C)O.Cl.Cl Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)/C=C/C4=CN(N=C4)C)O.Cl.Cl UBZQRNCSIRFQIO-YZQYOJQGSA-N 0.000 claims 4
- NAFABHZGWNKPBK-JSXJMZBESA-N C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=C(C=C4)N(N=C5)C)O.Cl.Cl Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=C(C=C4)N(N=C5)C)O.Cl.Cl NAFABHZGWNKPBK-JSXJMZBESA-N 0.000 claims 4
- USEFMPQBPUTANG-DUFSSLHGSA-N C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=C(C=C4)NN=C5)O.Cl.Cl Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=C(C=C4)NN=C5)O.Cl.Cl USEFMPQBPUTANG-DUFSSLHGSA-N 0.000 claims 4
- SLOUKZKTGRBLHR-DUFSSLHGSA-N C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl.Cl Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl.Cl SLOUKZKTGRBLHR-DUFSSLHGSA-N 0.000 claims 4
- FIDIKGXYLKWZCG-JSXJMZBESA-N C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)OC)C)O.Cl.Cl Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)OC)C)O.Cl.Cl FIDIKGXYLKWZCG-JSXJMZBESA-N 0.000 claims 4
- SYCGHNUUPNAKGP-DUFSSLHGSA-N C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CN5C(=NC=N5)C=C4)O.Cl.Cl Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CN5C(=NC=N5)C=C4)O.Cl.Cl SYCGHNUUPNAKGP-DUFSSLHGSA-N 0.000 claims 4
- AGJWNJVIDGLMDZ-JSXJMZBESA-N C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CN5C=C(N=C5C=C4)C)O.Cl.Cl Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CN5C=C(N=C5C=C4)C)O.Cl.Cl AGJWNJVIDGLMDZ-JSXJMZBESA-N 0.000 claims 4
- CZVYKFMDNFIDFO-KAECKJJSSA-N C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CN5C=C(N=C5N=C4)C)O.C(=O)(C(F)(F)F)O Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CN5C=C(N=C5N=C4)C)O.C(=O)(C(F)(F)F)O CZVYKFMDNFIDFO-KAECKJJSSA-N 0.000 claims 4
- JDSURZNYFBSUGQ-FYPKGCJUSA-N C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl JDSURZNYFBSUGQ-FYPKGCJUSA-N 0.000 claims 4
- HGMVQCQTYHLUSR-JSXJMZBESA-N C[C@@H]1CN(C[C@@H](N1C)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl.Cl Chemical compound C[C@@H]1CN(C[C@@H](N1C)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl.Cl HGMVQCQTYHLUSR-JSXJMZBESA-N 0.000 claims 4
- HFKUATCINGGITM-FQDOXHKTSA-N C[C@@H]1CN(C[C@@H](N1C)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl Chemical compound C[C@@H]1CN(C[C@@H](N1C)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl HFKUATCINGGITM-FQDOXHKTSA-N 0.000 claims 4
- DECYQCLCPJBWDO-YJBOKZPZSA-N FC1=C(C=NN1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O Chemical compound FC1=C(C=NN1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O DECYQCLCPJBWDO-YJBOKZPZSA-N 0.000 claims 4
- AESVNQVEJBWRDI-GASCZTMLSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](N([C@H](C1)C)C)C)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](N([C@H](C1)C)C)C)O AESVNQVEJBWRDI-GASCZTMLSA-N 0.000 claims 4
- WFYVRQWCNYKKIM-BETUJISGSA-N N1N=CC(=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](N([C@H](C1)C)C)C)O Chemical compound N1N=CC(=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](N([C@H](C1)C)C)C)O WFYVRQWCNYKKIM-BETUJISGSA-N 0.000 claims 4
- AGAQMRZEABRAMD-UHFFFAOYSA-N N1N=CC(=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O Chemical compound N1N=CC(=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O AGAQMRZEABRAMD-UHFFFAOYSA-N 0.000 claims 4
- FBIHDTBMGPGRHI-VPYROQPTSA-N 2-[6-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyridazin-3-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]pyridin-3-ol Chemical compound C(N1N=CC(=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O)([2H])([2H])[2H] FBIHDTBMGPGRHI-VPYROQPTSA-N 0.000 claims 2
- UDZAEWMURDKNIY-REDHCSJFSA-N 2-[6-[(3R)-3-(tert-butylamino)pyrrolidin-1-yl]pyridazin-3-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]pyridin-3-ol Chemical compound C(C)(C)(C)N[C@H]1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H] UDZAEWMURDKNIY-REDHCSJFSA-N 0.000 claims 2
- LMFOXRKPQPWMBX-CYQFQFRFSA-N 2-[6-[(3R,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]-5-(2-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)pyridin-3-ol trihydrochloride Chemical compound CC1=NN2C=C(C=CC2=N1)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O.Cl.Cl.Cl LMFOXRKPQPWMBX-CYQFQFRFSA-N 0.000 claims 2
- MZHUYPDLNAQKKT-CPEHYTGNSA-N 2-[6-[(3R,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]-5-(2-methylimidazo[1,2-a]pyridin-6-yl)pyridin-3-ol trihydrochloride Chemical compound CC1=CN2C=C(C=CC2=N1)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O.Cl.Cl.Cl MZHUYPDLNAQKKT-CPEHYTGNSA-N 0.000 claims 2
- OASWFGLMIQVGCL-CESJSFPBSA-N 2-[6-[(3R,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]-5-(2-methylimidazo[1,2-a]pyrimidin-6-yl)pyridin-3-ol trihydrochloride Chemical compound CC1=CN2C=C(C=NC2=N1)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O.Cl.Cl.Cl OASWFGLMIQVGCL-CESJSFPBSA-N 0.000 claims 2
- SBBKJFMLZNJVNX-JXFKEZNVSA-N 2-[6-[(3R,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]-5-([1,2,4]triazolo[1,5-a]pyrazin-2-yl)pyridin-3-ol Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NN2C(C=NC=C2)=N1)(C)C)(C)C SBBKJFMLZNJVNX-JXFKEZNVSA-N 0.000 claims 2
- POTPNCWOKPZJCM-UQASCPDOSA-N 2-[6-[(3R,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]-5-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]pyridin-3-ol trihydrochloride Chemical compound CC1=CN2C=C(C=C(C2=N1)C(F)(F)F)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O.Cl.Cl.Cl POTPNCWOKPZJCM-UQASCPDOSA-N 0.000 claims 2
- LMFOXRKPQPWMBX-LZYRFSMASA-N 2-[6-[(3S,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]-5-(2-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)pyridin-3-ol trihydrochloride Chemical compound CC1=NN2C=C(C=CC2=N1)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O.Cl.Cl.Cl LMFOXRKPQPWMBX-LZYRFSMASA-N 0.000 claims 2
- MZHUYPDLNAQKKT-YQWSPDFPSA-N 2-[6-[(3S,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]-5-(2-methylimidazo[1,2-a]pyridin-6-yl)pyridin-3-ol trihydrochloride Chemical compound CC1=CN2C=C(C=CC2=N1)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O.Cl.Cl.Cl MZHUYPDLNAQKKT-YQWSPDFPSA-N 0.000 claims 2
- OASWFGLMIQVGCL-VGNPVSFESA-N 2-[6-[(3S,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]-5-(2-methylimidazo[1,2-a]pyrimidin-6-yl)pyridin-3-ol trihydrochloride Chemical compound CC1=CN2C=C(C=NC2=N1)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O.Cl.Cl.Cl OASWFGLMIQVGCL-VGNPVSFESA-N 0.000 claims 2
- POTPNCWOKPZJCM-QNPMOXIUSA-N 2-[6-[(3S,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]-5-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]pyridin-3-ol trihydrochloride Chemical compound CC1=CN2C=C(C=C(C2=N1)C(F)(F)F)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O.Cl.Cl.Cl POTPNCWOKPZJCM-QNPMOXIUSA-N 0.000 claims 2
- PYVBNWBYLGFDBQ-JSXJMZBESA-N 2-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyridazin-3-yl]-5-[(6-methylpyridin-3-yl)amino]pyridin-3-ol dihydrochloride Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)NC4=CN=C(C=C4)C)O.Cl.Cl PYVBNWBYLGFDBQ-JSXJMZBESA-N 0.000 claims 2
- PIMZNXQDCRTYFK-HPRDVNIFSA-N 2-[6-[(5,5-dimethyl-4-azaspiro[2.5]octan-7-yl)oxy]pyridazin-3-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]pyridin-3-ol Chemical compound CC1(NC2(CC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H])C PIMZNXQDCRTYFK-HPRDVNIFSA-N 0.000 claims 2
- DVONPMSAMCXLJH-UHFFFAOYSA-N 2-[6-[(6,6-dimethyl-2-oxa-5-azaspiro[3.5]nonan-8-yl)oxy]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)pyridin-3-ol Chemical compound CC1(NC2(COC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)C DVONPMSAMCXLJH-UHFFFAOYSA-N 0.000 claims 2
- UDZAEWMURDKNIY-GKOSEXJESA-N 2-[6-[3-(tert-butylamino)pyrrolidin-1-yl]pyridazin-3-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]pyridin-3-ol Chemical compound C(C)(C)(C)NC1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H] UDZAEWMURDKNIY-GKOSEXJESA-N 0.000 claims 2
- XNPOOULYYABWIZ-NHPNDNCXSA-N 2-[6-[[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino]pyridazin-3-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]pyridin-3-ol Chemical compound F[C@H]1C(NC(C[C@H]1NC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H])(C)C)(C)C XNPOOULYYABWIZ-NHPNDNCXSA-N 0.000 claims 2
- OCXJONGFKVSVJJ-RGEXYPLXSA-N 2-[6-[[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino]pyridazin-3-yl]-5-[6-(trideuteriomethoxy)pyrimidin-4-yl]pyridin-3-ol Chemical compound F[C@H]1C(NC(C[C@H]1NC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NC=NC(=C1)OC([2H])([2H])[2H])(C)C)(C)C OCXJONGFKVSVJJ-RGEXYPLXSA-N 0.000 claims 2
- DHCOZZMTMPLPJX-FRYRKQBNSA-N 2-[6-[[(5R,7R)-5-methyl-4-azaspiro[2.5]octan-7-yl]oxy]pyridazin-3-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]pyridin-3-ol Chemical compound C[C@H]1NC2(CC2)C[C@@H](C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H] DHCOZZMTMPLPJX-FRYRKQBNSA-N 0.000 claims 2
- DHCOZZMTMPLPJX-JJHWETPOSA-N 2-[6-[[(5R,7S)-5-methyl-4-azaspiro[2.5]octan-7-yl]oxy]pyridazin-3-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]pyridin-3-ol Chemical compound C[C@H]1NC2(CC2)C[C@H](C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H] DHCOZZMTMPLPJX-JJHWETPOSA-N 0.000 claims 2
- DHCOZZMTMPLPJX-QEHOZGPLSA-N 2-[6-[[(5S,7R)-5-methyl-4-azaspiro[2.5]octan-7-yl]oxy]pyridazin-3-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]pyridin-3-ol Chemical compound C[C@@H]1NC2(CC2)C[C@@H](C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H] DHCOZZMTMPLPJX-QEHOZGPLSA-N 0.000 claims 2
- DHCOZZMTMPLPJX-VBYHJNFMSA-N 2-[6-[[(5S,7S)-5-methyl-4-azaspiro[2.5]octan-7-yl]oxy]pyridazin-3-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]pyridin-3-ol Chemical compound C[C@@H]1NC2(CC2)C[C@H](C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H] DHCOZZMTMPLPJX-VBYHJNFMSA-N 0.000 claims 2
- BZUUIAQPHOYZGJ-DCXNZVDVSA-N 5-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-2-[6-[(3R,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]pyridin-3-ol trihydrochloride Chemical compound CC1=CC(=CN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O.Cl.Cl.Cl BZUUIAQPHOYZGJ-DCXNZVDVSA-N 0.000 claims 2
- BZUUIAQPHOYZGJ-OKBDLKLZSA-N 5-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-2-[6-[(3S,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]pyridin-3-ol trihydrochloride Chemical compound CC1=CC(=CN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O.Cl.Cl.Cl BZUUIAQPHOYZGJ-OKBDLKLZSA-N 0.000 claims 2
- BQFHASXMOBLLJY-MMFWGRTPSA-N 5-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-2-[6-[(3R,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]pyridin-3-ol trihydrochloride Chemical compound CCC1=CC(=CN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O.Cl.Cl.Cl BQFHASXMOBLLJY-MMFWGRTPSA-N 0.000 claims 2
- BQFHASXMOBLLJY-PTVVCQEBSA-N 5-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-2-[6-[(3S,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]oxypyridazin-3-yl]pyridin-3-ol trihydrochloride Chemical compound CCC1=CC(=CN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O.Cl.Cl.Cl BQFHASXMOBLLJY-PTVVCQEBSA-N 0.000 claims 2
- JDUDPYOJDOETHD-UHFFFAOYSA-N 5-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-2-[6-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyridazin-3-yl]pyridin-3-ol dihydrochloride Chemical compound CC1=CN2C(=N1)C(=CC(=N2)C3=CC(=C(N=C3)C4=NN=C(C=C4)OC5CC(NC(C5)(C)C)(C)C)O)OC.Cl.Cl JDUDPYOJDOETHD-UHFFFAOYSA-N 0.000 claims 2
- WZJUHLHFBOTCGA-FEUJSUOTSA-N C(=O)OC=1C(=NC=C(C=1)C=1C=NN(C=1)C([2H])([2H])[2H])C=1N=NC(=CC=1)N[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F Chemical compound C(=O)OC=1C(=NC=C(C=1)C=1C=NN(C=1)C([2H])([2H])[2H])C=1N=NC(=CC=1)N[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F WZJUHLHFBOTCGA-FEUJSUOTSA-N 0.000 claims 2
- WZJUHLHFBOTCGA-IGWYIDSESA-N C(=O)OC=1C(=NC=C(C=1)C=1C=NN(C=1)C([2H])([2H])[2H])C=1N=NC(=CC=1)N[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F Chemical compound C(=O)OC=1C(=NC=C(C=1)C=1C=NN(C=1)C([2H])([2H])[2H])C=1N=NC(=CC=1)N[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F WZJUHLHFBOTCGA-IGWYIDSESA-N 0.000 claims 2
- FZDNNTNXYXFACG-OAHLLOKOSA-N C(C)(C)(C)N[C@H]1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CN=C(O1)C Chemical compound C(C)(C)(C)N[C@H]1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CN=C(O1)C FZDNNTNXYXFACG-OAHLLOKOSA-N 0.000 claims 2
- NCNDGFXSDFDQKK-OAHLLOKOSA-N C(C)(C)(C)N[C@H]1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NC=NC(=C1)OC Chemical compound C(C)(C)(C)N[C@H]1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NC=NC(=C1)OC NCNDGFXSDFDQKK-OAHLLOKOSA-N 0.000 claims 2
- LNZOITSVCMYZCO-CYBMUJFWSA-N C(C)(C)(C)N[C@H]1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1 Chemical compound C(C)(C)(C)N[C@H]1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1 LNZOITSVCMYZCO-CYBMUJFWSA-N 0.000 claims 2
- WHQRPEHDKAJBHE-UHFFFAOYSA-N C(C)C1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C Chemical compound C(C)C1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C WHQRPEHDKAJBHE-UHFFFAOYSA-N 0.000 claims 2
- MXXLQCOUCLLFSU-UHFFFAOYSA-N C(C)C1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 Chemical compound C(C)C1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 MXXLQCOUCLLFSU-UHFFFAOYSA-N 0.000 claims 2
- KPMQLXZPWZONJH-DHLKQENFSA-N C(C)C=1C=2N(C=C(C=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O)C=C(N=2)C Chemical compound C(C)C=1C=2N(C=C(C=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O)C=C(N=2)C KPMQLXZPWZONJH-DHLKQENFSA-N 0.000 claims 2
- KPMQLXZPWZONJH-RCZVLFRGSA-N C(C)C=1C=2N(C=C(C=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O)C=C(N=2)C Chemical compound C(C)C=1C=2N(C=C(C=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O)C=C(N=2)C KPMQLXZPWZONJH-RCZVLFRGSA-N 0.000 claims 2
- PHMMRFLYHRITGY-URXFXBBRSA-N C(C)C=1C=2N(N=C(C=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O)C=C(N=2)C Chemical compound C(C)C=1C=2N(N=C(C=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O)C=C(N=2)C PHMMRFLYHRITGY-URXFXBBRSA-N 0.000 claims 2
- PHMMRFLYHRITGY-ZJSXRUAMSA-N C(C)C=1C=2N(N=C(C=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O)C=C(N=2)C Chemical compound C(C)C=1C=2N(N=C(C=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O)C=C(N=2)C PHMMRFLYHRITGY-ZJSXRUAMSA-N 0.000 claims 2
- MXXLQCOUCLLFSU-AWEZNQCLSA-N C(C)[C@H]1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 Chemical compound C(C)[C@H]1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 MXXLQCOUCLLFSU-AWEZNQCLSA-N 0.000 claims 2
- BJZBYKGXGRAMDN-UHFFFAOYSA-N C1(CC1)C1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 Chemical compound C1(CC1)C1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 BJZBYKGXGRAMDN-UHFFFAOYSA-N 0.000 claims 2
- HFMLSCOYVZXECN-UHFFFAOYSA-N C1(CC1)N1CCN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C Chemical compound C1(CC1)N1CCN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C HFMLSCOYVZXECN-UHFFFAOYSA-N 0.000 claims 2
- LFOAPBSNNALFGK-JCNGFBMWSA-N C1(CC1)[C@H]1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H] Chemical compound C1(CC1)[C@H]1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H] LFOAPBSNNALFGK-JCNGFBMWSA-N 0.000 claims 2
- ACDOAQVTWJVTBW-OAHLLOKOSA-N C1(CC1)[C@H]1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1 Chemical compound C1(CC1)[C@H]1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1 ACDOAQVTWJVTBW-OAHLLOKOSA-N 0.000 claims 2
- APANAEVLXSWKNS-UHFFFAOYSA-N C12N(CC(NC1)C2)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C Chemical compound C12N(CC(NC1)C2)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C APANAEVLXSWKNS-UHFFFAOYSA-N 0.000 claims 2
- CLVWEHWUCWUSMV-UHFFFAOYSA-N C12N(CC(NC1)C2)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NC=2N(C=1)C=C(N=2)C Chemical compound C12N(CC(NC1)C2)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NC=2N(C=1)C=C(N=2)C CLVWEHWUCWUSMV-UHFFFAOYSA-N 0.000 claims 2
- AMNZDDCMBQPNJI-UHFFFAOYSA-N C1CC11NCCN(C1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C Chemical compound C1CC11NCCN(C1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C AMNZDDCMBQPNJI-UHFFFAOYSA-N 0.000 claims 2
- XCCXGCTUKSGJAT-UHFFFAOYSA-N C1CC1C2CN(CCN2)C3=NN=C(C=C3)C4=C(C=C(C=N4)C5=CNN=C5)O.Cl.Cl Chemical compound C1CC1C2CN(CCN2)C3=NN=C(C=C3)C4=C(C=C(C=N4)C5=CNN=C5)O.Cl.Cl XCCXGCTUKSGJAT-UHFFFAOYSA-N 0.000 claims 2
- UULUMZRJFVNZOF-QCUBGVIVSA-N C1CC1[C@H]2CN(CCN2)C3=NN=C(C=C3)C4=C(C=C(C=N4)N5N=CC=N5)O.Cl.Cl Chemical compound C1CC1[C@H]2CN(CCN2)C3=NN=C(C=C3)C4=C(C=C(C=N4)N5N=CC=N5)O.Cl.Cl UULUMZRJFVNZOF-QCUBGVIVSA-N 0.000 claims 2
- IGLVNAJAFWQCCJ-ONEGZZNKSA-N CC(C)C1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)\C=C\C=1C=NNC=1 Chemical compound CC(C)C1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)\C=C\C=1C=NNC=1 IGLVNAJAFWQCCJ-ONEGZZNKSA-N 0.000 claims 2
- RERVTFVGOCKPGI-CZEFNJPISA-N CC(C)C1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)/C=C/C4=CNN=C4)O.Cl.Cl Chemical compound CC(C)C1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)/C=C/C4=CNN=C4)O.Cl.Cl RERVTFVGOCKPGI-CZEFNJPISA-N 0.000 claims 2
- BYHATNXGRGORQX-INIZCTEOSA-N CC(C)[C@@H]1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 Chemical compound CC(C)[C@@H]1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 BYHATNXGRGORQX-INIZCTEOSA-N 0.000 claims 2
- WVWAVCPWMCZACN-SQKCAUCHSA-N CC(C)[C@@H]1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl Chemical compound CC(C)[C@@H]1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl WVWAVCPWMCZACN-SQKCAUCHSA-N 0.000 claims 2
- BYHATNXGRGORQX-MRXNPFEDSA-N CC(C)[C@H]1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 Chemical compound CC(C)[C@H]1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1 BYHATNXGRGORQX-MRXNPFEDSA-N 0.000 claims 2
- PVOMEMNVOQLKPH-FAVHNTAZSA-N CC(C)[C@H]1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl.Cl Chemical compound CC(C)[C@H]1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl.Cl PVOMEMNVOQLKPH-FAVHNTAZSA-N 0.000 claims 2
- WVWAVCPWMCZACN-GGMCWBHBSA-N CC(C)[C@H]1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl Chemical compound CC(C)[C@H]1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl WVWAVCPWMCZACN-GGMCWBHBSA-N 0.000 claims 2
- DBRIQQYJVNZPEC-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N(C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)N(C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.Cl.Cl DBRIQQYJVNZPEC-UHFFFAOYSA-N 0.000 claims 2
- GBYOJZADGUVTBA-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC(=NC=N4)OC)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC(=NC=N4)OC)O)C.Cl.Cl GBYOJZADGUVTBA-UHFFFAOYSA-N 0.000 claims 2
- WXHPTNHDHOWCRU-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)C#N)C)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)C#N)C)O)C.Cl.Cl WXHPTNHDHOWCRU-UHFFFAOYSA-N 0.000 claims 2
- WRBJRTIILZOFSG-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O)C.Cl.Cl WRBJRTIILZOFSG-UHFFFAOYSA-N 0.000 claims 2
- RACZAPUJVCQMOI-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=NN5C=CN=C5C=C4)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=NN5C=CN=C5C=C4)O)C.Cl.Cl RACZAPUJVCQMOI-UHFFFAOYSA-N 0.000 claims 2
- KXUDWKSINJNOFA-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=N3)N4C=NC=N4)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=N3)N4C=NC=N4)O)C.Cl.Cl KXUDWKSINJNOFA-UHFFFAOYSA-N 0.000 claims 2
- MDHWEONDGYHHBS-UHFFFAOYSA-N CC1(CC(CC2(N1)CC2)N(C)C3=NN=C(C=C3)C4=C(C=C(C=N4)C5=CC6=CN(N=C6C(=C5)F)C)O)C.Cl.Cl Chemical compound CC1(CC(CC2(N1)CC2)N(C)C3=NN=C(C=C3)C4=C(C=C(C=N4)C5=CC6=CN(N=C6C(=C5)F)C)O)C.Cl.Cl MDHWEONDGYHHBS-UHFFFAOYSA-N 0.000 claims 2
- RINAWYNTTRKJLG-UHFFFAOYSA-N CC1(CC(CC2(N1)CC2)OC3=NN=C(C=C3)C4=C(C=C(C=N4)C5=CNN=C5)O)C.Cl.Cl Chemical compound CC1(CC(CC2(N1)CC2)OC3=NN=C(C=C3)C4=C(C=C(C=N4)C5=CNN=C5)O)C.Cl.Cl RINAWYNTTRKJLG-UHFFFAOYSA-N 0.000 claims 2
- XNPDRPRCTVTENB-UHFFFAOYSA-N CC1(CC(CC2(N1)CC2)OC3=NN=C(C=C3)C4=C(C=C(C=N4)C5=NC=CO5)O)C.Cl.Cl Chemical compound CC1(CC(CC2(N1)CC2)OC3=NN=C(C=C3)C4=C(C=C(C=N4)C5=NC=CO5)O)C.Cl.Cl XNPDRPRCTVTENB-UHFFFAOYSA-N 0.000 claims 2
- YQHGFFCZBCTOKJ-UHFFFAOYSA-N CC1(CC(CC2(N1)CC2)OC3=NN=C(C=C3)C4=C(C=C(C=N4)N5N=CC=N5)O)C.Cl.Cl Chemical compound CC1(CC(CC2(N1)CC2)OC3=NN=C(C=C3)C4=C(C=C(C=N4)N5N=CC=N5)O)C.Cl.Cl YQHGFFCZBCTOKJ-UHFFFAOYSA-N 0.000 claims 2
- KFZCTWJAAHUBOW-UHFFFAOYSA-N CC1(CN(CC(N1)(C)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O)C.Cl Chemical compound CC1(CN(CC(N1)(C)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O)C.Cl KFZCTWJAAHUBOW-UHFFFAOYSA-N 0.000 claims 2
- PCAFPTIZNDFQHV-UHFFFAOYSA-N CC1(CN(CC(N1)(C)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.Cl Chemical compound CC1(CN(CC(N1)(C)C)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.Cl PCAFPTIZNDFQHV-UHFFFAOYSA-N 0.000 claims 2
- FHZOTUIUSLSFDU-QSVLQNJRSA-N CC1(C[C@@H]([C@@H](C(N1)(C)C)F)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.Cl Chemical compound CC1(C[C@@H]([C@@H](C(N1)(C)C)F)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.Cl FHZOTUIUSLSFDU-QSVLQNJRSA-N 0.000 claims 2
- GCYBKBPDFZFQGA-BZKLBDBUSA-N CC1(C[C@@H]([C@@H](C(N1)(C)C)F)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=NN5C=CN=C5C=C4)O)C.Cl.Cl Chemical compound CC1(C[C@@H]([C@@H](C(N1)(C)C)F)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=NN5C=CN=C5C=C4)O)C.Cl.Cl GCYBKBPDFZFQGA-BZKLBDBUSA-N 0.000 claims 2
- BFFJLTCFMLWERL-KQKCUOLZSA-N CC1(C[C@H]([C@H](C(N1)(C)C)F)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=C(NN=C4)F)O)C.Cl Chemical compound CC1(C[C@H]([C@H](C(N1)(C)C)F)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=C(NN=C4)F)O)C.Cl BFFJLTCFMLWERL-KQKCUOLZSA-N 0.000 claims 2
- GCYBKBPDFZFQGA-VMJMSTHCSA-N CC1(C[C@H]([C@H](C(N1)(C)C)F)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=NN5C=CN=C5C=C4)O)C.Cl.Cl Chemical compound CC1(C[C@H]([C@H](C(N1)(C)C)F)OC2=NN=C(C=C2)C3=C(C=C(C=N3)C4=NN5C=CN=C5C=C4)O)C.Cl.Cl GCYBKBPDFZFQGA-VMJMSTHCSA-N 0.000 claims 2
- ANWJHYUVVWKJMZ-UHFFFAOYSA-N CC1(NC(CC(C1)OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC2=CN(N=C2C(=C1)C#N)C)O)(C)C)C Chemical compound CC1(NC(CC(C1)OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC2=CN(N=C2C(=C1)C#N)C)O)(C)C)C ANWJHYUVVWKJMZ-UHFFFAOYSA-N 0.000 claims 2
- VLOPZXGDDSCTFL-UHFFFAOYSA-N CC1(NC(CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)(C)C)C Chemical compound CC1(NC(CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)(C)C)C VLOPZXGDDSCTFL-UHFFFAOYSA-N 0.000 claims 2
- JIERUBNBBPHRSM-UHFFFAOYSA-N CC1(NC(CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CN=C1)(C)C)C Chemical compound CC1(NC(CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CN=C1)(C)C)C JIERUBNBBPHRSM-UHFFFAOYSA-N 0.000 claims 2
- DDDSPBNPIYQQBW-UHFFFAOYSA-N CC1(NC(CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=NC=C1)(C)C)C Chemical compound CC1(NC(CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=NC=C1)(C)C)C DDDSPBNPIYQQBW-UHFFFAOYSA-N 0.000 claims 2
- NTNGFCRFWHWNPP-UHFFFAOYSA-N CC1(NC2(CC2)CC(C1)N(C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C)C)C Chemical compound CC1(NC2(CC2)CC(C1)N(C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C)C)C NTNGFCRFWHWNPP-UHFFFAOYSA-N 0.000 claims 2
- XTNDDOMTDGOHPB-HPRDVNIFSA-N CC1(NC2(CC2)CC(C1)N(C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H])C)C Chemical compound CC1(NC2(CC2)CC(C1)N(C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H])C)C XTNDDOMTDGOHPB-HPRDVNIFSA-N 0.000 claims 2
- GCTZCFBQTGQESC-UHFFFAOYSA-N CC1(NC2(CC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)C Chemical compound CC1(NC2(CC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)C GCTZCFBQTGQESC-UHFFFAOYSA-N 0.000 claims 2
- PWEJQJUFTGNHOY-UHFFFAOYSA-N CC1(NC2(CC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1OC=CN=1)C Chemical compound CC1(NC2(CC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1OC=CN=1)C PWEJQJUFTGNHOY-UHFFFAOYSA-N 0.000 claims 2
- FRSNMKYMNIWVHS-UHFFFAOYSA-N CC1(NC2(CC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1SC=CN=1)C Chemical compound CC1(NC2(CC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1SC=CN=1)C FRSNMKYMNIWVHS-UHFFFAOYSA-N 0.000 claims 2
- LIMVAQNZUUORMM-UHFFFAOYSA-N CC1(NC2(CC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)C Chemical compound CC1(NC2(CC2)CC(C1)OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)C LIMVAQNZUUORMM-UHFFFAOYSA-N 0.000 claims 2
- CPARRGDGPQTJRB-DPAQORBOSA-N CC1=CC(=CC2=C1N=C(O2)C)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O.Cl.Cl Chemical compound CC1=CC(=CC2=C1N=C(O2)C)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O.Cl.Cl CPARRGDGPQTJRB-DPAQORBOSA-N 0.000 claims 2
- CPARRGDGPQTJRB-XLHHTRKNSA-N CC1=CC(=CC2=C1N=C(O2)C)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O.Cl.Cl Chemical compound CC1=CC(=CC2=C1N=C(O2)C)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O.Cl.Cl CPARRGDGPQTJRB-XLHHTRKNSA-N 0.000 claims 2
- ZIDFSFFLNMQIDB-UHFFFAOYSA-N CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=NN=C(C=C4)OC5CC(NC(C5)(C)C)(C)C)O.Cl.Cl Chemical compound CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=NN=C(C=C4)OC5CC(NC(C5)(C)C)(C)C)O.Cl.Cl ZIDFSFFLNMQIDB-UHFFFAOYSA-N 0.000 claims 2
- HLVQGEBDNGSANE-LJQANCHMSA-N CC1=CC=C(C=N1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](NCC1)C(C)C)O Chemical compound CC1=CC=C(C=N1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](NCC1)C(C)C)O HLVQGEBDNGSANE-LJQANCHMSA-N 0.000 claims 2
- HLVQGEBDNGSANE-IBGZPJMESA-N CC1=CC=C(C=N1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](NCC1)C(C)C)O Chemical compound CC1=CC=C(C=N1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](NCC1)C(C)C)O HLVQGEBDNGSANE-IBGZPJMESA-N 0.000 claims 2
- PMZLPATZQHXWIR-LRHYEEQISA-N CC1=CN2C(=N1)C(=CC(=N2)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O)OC.Cl.Cl Chemical compound CC1=CN2C(=N1)C(=CC(=N2)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O)OC.Cl.Cl PMZLPATZQHXWIR-LRHYEEQISA-N 0.000 claims 2
- PMZLPATZQHXWIR-KBVFCZPLSA-N CC1=CN2C(=N1)C(=CC(=N2)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O)OC.Cl.Cl Chemical compound CC1=CN2C(=N1)C(=CC(=N2)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O)OC.Cl.Cl PMZLPATZQHXWIR-KBVFCZPLSA-N 0.000 claims 2
- ADCADNPXQTZVJH-CHOFETAFSA-N CC1=CN2C(=N1)C=CC(=N2)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O.Cl.Cl Chemical compound CC1=CN2C(=N1)C=CC(=N2)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@@H]5CC(NC([C@@H]5F)(C)C)(C)C)O.Cl.Cl ADCADNPXQTZVJH-CHOFETAFSA-N 0.000 claims 2
- ADCADNPXQTZVJH-HXTKCBNGSA-N CC1=CN2C(=N1)C=CC(=N2)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O.Cl.Cl Chemical compound CC1=CN2C(=N1)C=CC(=N2)C3=CC(=C(N=C3)C4=NN=C(C=C4)O[C@H]5CC(NC([C@H]5F)(C)C)(C)C)O.Cl.Cl ADCADNPXQTZVJH-HXTKCBNGSA-N 0.000 claims 2
- VFDRSVGQUZQANM-UHFFFAOYSA-N CC1=CN2C=C(C=CC2=N1)C3=CC(=C(N=C3)C4=NN=C(C=C4)N5CCC6(C5)CCN6)O.Cl.Cl Chemical compound CC1=CN2C=C(C=CC2=N1)C3=CC(=C(N=C3)C4=NN=C(C=C4)N5CCC6(C5)CCN6)O.Cl.Cl VFDRSVGQUZQANM-UHFFFAOYSA-N 0.000 claims 2
- MRVKMINACXJTDT-UHFFFAOYSA-N CC1=CN2C=C(C=NC2=N1)C3=CC(=C(N=C3)C4=NN=C(C=C4)N5CC6CC5CN6)O.C(=O)(C(F)(F)F)O Chemical compound CC1=CN2C=C(C=NC2=N1)C3=CC(=C(N=C3)C4=NN=C(C=C4)N5CC6CC5CN6)O.C(=O)(C(F)(F)F)O MRVKMINACXJTDT-UHFFFAOYSA-N 0.000 claims 2
- BOMJWXWISNFOCT-RMRYJAPISA-N CC1=CN=C(C=N1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@@H](C4)C(C)C)O.Cl.Cl Chemical compound CC1=CN=C(C=N1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@@H](C4)C(C)C)O.Cl.Cl BOMJWXWISNFOCT-RMRYJAPISA-N 0.000 claims 2
- BOMJWXWISNFOCT-ZEECNFPPSA-N CC1=CN=C(C=N1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@H](C4)C(C)C)O.Cl.Cl Chemical compound CC1=CN=C(C=N1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@H](C4)C(C)C)O.Cl.Cl BOMJWXWISNFOCT-ZEECNFPPSA-N 0.000 claims 2
- JUFYQBQABGOSSA-TXEPZDRESA-N CC1=NC=C(C=C1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@@H](C4)C(C)C)O.Cl.Cl Chemical compound CC1=NC=C(C=C1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@@H](C4)C(C)C)O.Cl.Cl JUFYQBQABGOSSA-TXEPZDRESA-N 0.000 claims 2
- JUFYQBQABGOSSA-JQDLGSOUSA-N CC1=NC=C(C=C1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@H](C4)C(C)C)O.Cl.Cl Chemical compound CC1=NC=C(C=C1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@H](C4)C(C)C)O.Cl.Cl JUFYQBQABGOSSA-JQDLGSOUSA-N 0.000 claims 2
- YXTBIWDJCIYOOC-NTEVMMBTSA-N CC1=NC=C(C=N1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@@H](C4)C(C)C)O.Cl.Cl Chemical compound CC1=NC=C(C=N1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@@H](C4)C(C)C)O.Cl.Cl YXTBIWDJCIYOOC-NTEVMMBTSA-N 0.000 claims 2
- YXTBIWDJCIYOOC-JPKZNVRTSA-N CC1=NC=C(C=N1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@H](C4)C(C)C)O.Cl.Cl Chemical compound CC1=NC=C(C=N1)NC2=CC(=C(N=C2)C3=NN=C(C=C3)N4CCN[C@H](C4)C(C)C)O.Cl.Cl YXTBIWDJCIYOOC-JPKZNVRTSA-N 0.000 claims 2
- IFAWKMVHFCXUBY-GOSISDBHSA-N CC1=NC=C(C=N1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](NCC1)C(C)C)O Chemical compound CC1=NC=C(C=N1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](NCC1)C(C)C)O IFAWKMVHFCXUBY-GOSISDBHSA-N 0.000 claims 2
- IFAWKMVHFCXUBY-SFHVURJKSA-N CC1=NC=C(C=N1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](NCC1)C(C)C)O Chemical compound CC1=NC=C(C=N1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](NCC1)C(C)C)O IFAWKMVHFCXUBY-SFHVURJKSA-N 0.000 claims 2
- GSIWWWYEDXCBNX-QCUBGVIVSA-N CC1=NC=C(O1)C2=CC(=C(N=C2)C3=NN=C(C=C3)N4CC[C@H](C4)NC(C)(C)C)O.Cl.Cl Chemical compound CC1=NC=C(O1)C2=CC(=C(N=C2)C3=NN=C(C=C3)N4CC[C@H](C4)NC(C)(C)C)O.Cl.Cl GSIWWWYEDXCBNX-QCUBGVIVSA-N 0.000 claims 2
- PNNFOWQRUPFGLZ-UHFFFAOYSA-N CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NC=1C=NC=CC=1 Chemical compound CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NC=1C=NC=CC=1 PNNFOWQRUPFGLZ-UHFFFAOYSA-N 0.000 claims 2
- BZHFIHYFXXRPQM-UHFFFAOYSA-N CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC1=CC=NC=C1 Chemical compound CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC1=CC=NC=C1 BZHFIHYFXXRPQM-UHFFFAOYSA-N 0.000 claims 2
- DIOZSOSDLMWHFZ-UHFFFAOYSA-N CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC1=NC=CC=C1 Chemical compound CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC1=NC=CC=C1 DIOZSOSDLMWHFZ-UHFFFAOYSA-N 0.000 claims 2
- VOHDLKARONJNQL-UHFFFAOYSA-N CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC=1C(=NNC=1)C Chemical compound CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC=1C(=NNC=1)C VOHDLKARONJNQL-UHFFFAOYSA-N 0.000 claims 2
- OXDOJRBSQLEWQS-UHFFFAOYSA-N CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC=1C=CC=C2C=CC=NC=12 Chemical compound CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC=1C=CC=C2C=CC=NC=12 OXDOJRBSQLEWQS-UHFFFAOYSA-N 0.000 claims 2
- WMLIXNQEJMVFHU-UHFFFAOYSA-N CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC=1C=NC2=CC=CC=C2C=1 Chemical compound CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC=1C=NC2=CC=CC=C2C=1 WMLIXNQEJMVFHU-UHFFFAOYSA-N 0.000 claims 2
- YGRYXJHUKWARRY-UHFFFAOYSA-N CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC=1C=NC=CC=1 Chemical compound CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC=1C=NC=CC=1 YGRYXJHUKWARRY-UHFFFAOYSA-N 0.000 claims 2
- MYZRNKHUAARXHI-UHFFFAOYSA-N CC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)OC)C)O.Cl.Cl Chemical compound CC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)OC)C)O.Cl.Cl MYZRNKHUAARXHI-UHFFFAOYSA-N 0.000 claims 2
- MLYHNYFSWIGVMP-UHFFFAOYSA-N CC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)NC4=CN=CC=C4)O.Cl.Cl Chemical compound CC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)NC4=CN=CC=C4)O.Cl.Cl MLYHNYFSWIGVMP-UHFFFAOYSA-N 0.000 claims 2
- GERWOMFXSYDLOE-UHFFFAOYSA-N CC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)NCC4=CC=CC5=C4N=CC=C5)O.Cl.Cl Chemical compound CC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)NCC4=CC=CC5=C4N=CC=C5)O.Cl.Cl GERWOMFXSYDLOE-UHFFFAOYSA-N 0.000 claims 2
- NTPMUQCHBWQWRE-UHFFFAOYSA-N CC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)NCC4=CC=CC=N4)O.Cl.Cl Chemical compound CC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)NCC4=CC=CC=N4)O.Cl.Cl NTPMUQCHBWQWRE-UHFFFAOYSA-N 0.000 claims 2
- BEXFFOHMKHCWML-UHFFFAOYSA-N CC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)NCC4=CN=CC=C4)O.Cl.Cl Chemical compound CC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)NCC4=CN=CC=C4)O.Cl.Cl BEXFFOHMKHCWML-UHFFFAOYSA-N 0.000 claims 2
- QXYIEMWRELNANO-DHLKQENFSA-N CC=1C=2N(C=C(N=1)C)C=C(C=2)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O Chemical compound CC=1C=2N(C=C(N=1)C)C=C(C=2)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O QXYIEMWRELNANO-DHLKQENFSA-N 0.000 claims 2
- QXYIEMWRELNANO-RCZVLFRGSA-N CC=1C=2N(C=C(N=1)C)C=C(C=2)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O Chemical compound CC=1C=2N(C=C(N=1)C)C=C(C=2)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O QXYIEMWRELNANO-RCZVLFRGSA-N 0.000 claims 2
- BFYXYQSPOQSCFF-URXFXBBRSA-N CC=1N=C2N(C=C(C=C2C)C=2C=C(C(=NC=2)C=2N=NC(=CC=2)O[C@@H]2[C@@H](C(NC(C2)(C)C)(C)C)F)O)C=1 Chemical compound CC=1N=C2N(C=C(C=C2C)C=2C=C(C(=NC=2)C=2N=NC(=CC=2)O[C@@H]2[C@@H](C(NC(C2)(C)C)(C)C)F)O)C=1 BFYXYQSPOQSCFF-URXFXBBRSA-N 0.000 claims 2
- BFYXYQSPOQSCFF-ZJSXRUAMSA-N CC=1N=C2N(C=C(C=C2C)C=2C=C(C(=NC=2)C=2N=NC(=CC=2)O[C@H]2[C@H](C(NC(C2)(C)C)(C)C)F)O)C=1 Chemical compound CC=1N=C2N(C=C(C=C2C)C=2C=C(C(=NC=2)C=2N=NC(=CC=2)O[C@H]2[C@H](C(NC(C2)(C)C)(C)C)F)O)C=1 BFYXYQSPOQSCFF-ZJSXRUAMSA-N 0.000 claims 2
- GXJKKDUFBBFINL-UHFFFAOYSA-N CC=1N=C2N(N=C(C=C2C)C=2C=C(C(=NC=2)C=2N=NC(=CC=2)OC2CC(NC(C2)(C)C)(C)C)O)C=1 Chemical compound CC=1N=C2N(N=C(C=C2C)C=2C=C(C(=NC=2)C=2N=NC(=CC=2)OC2CC(NC(C2)(C)C)(C)C)O)C=1 GXJKKDUFBBFINL-UHFFFAOYSA-N 0.000 claims 2
- UDMFBPAVUMVLHJ-QGZVFWFLSA-N CC=1N=CC(=NC=1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](NCC1)C(C)C)O Chemical compound CC=1N=CC(=NC=1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](NCC1)C(C)C)O UDMFBPAVUMVLHJ-QGZVFWFLSA-N 0.000 claims 2
- UDMFBPAVUMVLHJ-KRWDZBQOSA-N CC=1N=CC(=NC=1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](NCC1)C(C)C)O Chemical compound CC=1N=CC(=NC=1)NC=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](NCC1)C(C)C)O UDMFBPAVUMVLHJ-KRWDZBQOSA-N 0.000 claims 2
- IKWVJFZWDRUQMH-OFVILXPXSA-N CC=1OC2=C(N=1)C(=CC(=C2)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O)C Chemical compound CC=1OC2=C(N=1)C(=CC(=C2)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O)C IKWVJFZWDRUQMH-OFVILXPXSA-N 0.000 claims 2
- IKWVJFZWDRUQMH-PXDATVDWSA-N CC=1OC2=C(N=1)C(=CC(=C2)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O)C Chemical compound CC=1OC2=C(N=1)C(=CC(=C2)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O)C IKWVJFZWDRUQMH-PXDATVDWSA-N 0.000 claims 2
- BQKZBWUFKQHWHU-UHFFFAOYSA-N CCC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl.Cl Chemical compound CCC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl.Cl BQKZBWUFKQHWHU-UHFFFAOYSA-N 0.000 claims 2
- VGLZFMVVAIINTM-UHFFFAOYSA-N CCC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl Chemical compound CCC1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl VGLZFMVVAIINTM-UHFFFAOYSA-N 0.000 claims 2
- VGLZFMVVAIINTM-UTLKBRERSA-N CC[C@H]1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl Chemical compound CC[C@H]1CN(CCN1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl.Cl VGLZFMVVAIINTM-UTLKBRERSA-N 0.000 claims 2
- FUDIPSVRPYAZPD-UHFFFAOYSA-N CN(C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)C1CC(NC(C1)(C)C)(C)C Chemical compound CN(C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)C1CC(NC(C1)(C)C)(C)C FUDIPSVRPYAZPD-UHFFFAOYSA-N 0.000 claims 2
- ANLDXQODQMZXEV-UHFFFAOYSA-N CN(C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1OC=CN=1)C1CC(NC(C1)(C)C)(C)C Chemical compound CN(C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1OC=CN=1)C1CC(NC(C1)(C)C)(C)C ANLDXQODQMZXEV-UHFFFAOYSA-N 0.000 claims 2
- OCGJADQSZFDXFS-UHFFFAOYSA-N CN1C=C2C=C(C=C(C2=N1)F)C3=CC(=C(N=C3)C4=NN=C(C=C4)N5CC6CC5CN6)O.Cl Chemical compound CN1C=C2C=C(C=C(C2=N1)F)C3=CC(=C(N=C3)C4=NN=C(C=C4)N5CC6CC5CN6)O.Cl OCGJADQSZFDXFS-UHFFFAOYSA-N 0.000 claims 2
- GPGYTXIFKAZYAI-UHFFFAOYSA-N CN1CCN(CC1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl.Cl Chemical compound CN1CCN(CC1)C2=NN=C(C=C2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl.Cl GPGYTXIFKAZYAI-UHFFFAOYSA-N 0.000 claims 2
- LBHWJHFIUJYYNX-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N(C1CC(NC(C1)(C)C)(C)C)C)O Chemical compound CN1N=C(C=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N(C1CC(NC(C1)(C)C)(C)C)C)O LBHWJHFIUJYYNX-UHFFFAOYSA-N 0.000 claims 2
- ZHHNJAQENPWVDC-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O Chemical compound CN1N=C(C=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O ZHHNJAQENPWVDC-UHFFFAOYSA-N 0.000 claims 2
- UAYVLBOYTOJSGS-CYBMUJFWSA-N CN[C@H]1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CN=C(O1)C Chemical compound CN[C@H]1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CN=C(O1)C UAYVLBOYTOJSGS-CYBMUJFWSA-N 0.000 claims 2
- SZUQPUZQFXTOKC-GFCCVEGCSA-N CN[C@H]1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1OC=CN=1 Chemical compound CN[C@H]1CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1OC=CN=1 SZUQPUZQFXTOKC-GFCCVEGCSA-N 0.000 claims 2
- KSOZDALESRUWRW-UHFFFAOYSA-N COC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CC(NCC1)C)O Chemical compound COC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CC(NCC1)C)O KSOZDALESRUWRW-UHFFFAOYSA-N 0.000 claims 2
- IXJOYKNATYJZMW-CYBMUJFWSA-N COC1=CC(=NC=N1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](CC1)NC)O Chemical compound COC1=CC(=NC=N1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](CC1)NC)O IXJOYKNATYJZMW-CYBMUJFWSA-N 0.000 claims 2
- VMHUYCQUHCIZMX-UHFFFAOYSA-N COC1=CC(=NC=N1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O Chemical compound COC1=CC(=NC=N1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O VMHUYCQUHCIZMX-UHFFFAOYSA-N 0.000 claims 2
- MAFAEVVBVQHLPI-UHFFFAOYSA-N COC=1C=2N(N=C(C=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O)C=C(N=2)C Chemical compound COC=1C=2N(N=C(C=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O)C=C(N=2)C MAFAEVVBVQHLPI-UHFFFAOYSA-N 0.000 claims 2
- VFELWWSPAZXBCL-GASCZTMLSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)NC=1C=NC(=CC=1)C Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)NC=1C=NC(=CC=1)C VFELWWSPAZXBCL-GASCZTMLSA-N 0.000 claims 2
- VRVWKKLLBJBEEO-BETUJISGSA-N C[C@@H]1CN(C[C@@H](N1)C)C1=CN=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C Chemical compound C[C@@H]1CN(C[C@@H](N1)C)C1=CN=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C VRVWKKLLBJBEEO-BETUJISGSA-N 0.000 claims 2
- PZJIPXYCKROSLJ-ZIAGYGMSSA-N C[C@@H]1CN(C[C@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C Chemical compound C[C@@H]1CN(C[C@H](N1)C)C1=CC=C(N=N1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C PZJIPXYCKROSLJ-ZIAGYGMSSA-N 0.000 claims 2
- CLLNLSCYKAPKQE-UHFFFAOYSA-N Cl.Cl.CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC=1C(=NNC=1)C Chemical compound Cl.Cl.CC1CN(CCN1)C1=CC=C(N=N1)C1=NC=C(C=C1O)NCC=1C(=NNC=1)C CLLNLSCYKAPKQE-UHFFFAOYSA-N 0.000 claims 2
- DBGLYJQFDSQKNX-UHFFFAOYSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CC(NC(C1)(C)C)(C)C)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CC(NC(C1)(C)C)(C)C)O DBGLYJQFDSQKNX-UHFFFAOYSA-N 0.000 claims 2
- VPITZAQAKVSCJY-UHFFFAOYSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CC(NCC1)C)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CC(NCC1)C)O VPITZAQAKVSCJY-UHFFFAOYSA-N 0.000 claims 2
- YPBZEURBCPSCDB-UHFFFAOYSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CCN(CC1)C)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CCN(CC1)C)O YPBZEURBCPSCDB-UHFFFAOYSA-N 0.000 claims 2
- GMBLKQNBSNGUGP-UHFFFAOYSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CCNCC1)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CCNCC1)O GMBLKQNBSNGUGP-UHFFFAOYSA-N 0.000 claims 2
- NUMHIFSELIBGRR-HXUWFJFHSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](NCC1)C(C)C)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](NCC1)C(C)C)O NUMHIFSELIBGRR-HXUWFJFHSA-N 0.000 claims 2
- VPITZAQAKVSCJY-ZDUSSCGKSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](NCC1)C)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@@H](NCC1)C)O VPITZAQAKVSCJY-ZDUSSCGKSA-N 0.000 claims 2
- VPITZAQAKVSCJY-CYBMUJFWSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](NCC1)C)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1C[C@H](NCC1)C)O VPITZAQAKVSCJY-CYBMUJFWSA-N 0.000 claims 2
- KONFFFFMQXSSIX-UHFFFAOYSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O KONFFFFMQXSSIX-UHFFFAOYSA-N 0.000 claims 2
- BBMZUVRWZKVAMI-RDPSFJRHSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O BBMZUVRWZKVAMI-RDPSFJRHSA-N 0.000 claims 2
- BBMZUVRWZKVAMI-HYBUGGRVSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O BBMZUVRWZKVAMI-HYBUGGRVSA-N 0.000 claims 2
- CNTWXHOCWIRZRR-RDPSFJRHSA-N FC1=CC=C(C2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O Chemical compound FC1=CC=C(C2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F)O CNTWXHOCWIRZRR-RDPSFJRHSA-N 0.000 claims 2
- CNTWXHOCWIRZRR-HYBUGGRVSA-N FC1=CC=C(C2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O Chemical compound FC1=CC=C(C2=CN(N=C12)C)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)O[C@H]1[C@H](C(NC(C1)(C)C)(C)C)F)O CNTWXHOCWIRZRR-HYBUGGRVSA-N 0.000 claims 2
- OXSFIWISPHERGW-KXBFYZLASA-N F[C@@H]1C(NC(C[C@@H]1NC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NNC=C1)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1NC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NNC=C1)(C)C)(C)C OXSFIWISPHERGW-KXBFYZLASA-N 0.000 claims 2
- XNPOOULYYABWIZ-QMYZHSFRSA-N F[C@@H]1C(NC(C[C@@H]1NC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H])(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1NC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H])(C)C)(C)C XNPOOULYYABWIZ-QMYZHSFRSA-N 0.000 claims 2
- DLSVDVRXSDKJPP-AVRDEDQJSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC(N(C=C1)C)=O)O)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC(N(C=C1)C)=O)O)(C)C)(C)C DLSVDVRXSDKJPP-AVRDEDQJSA-N 0.000 claims 2
- VIRSMLQZWDAGLJ-UWJYYQICSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC(N(C=N1)C)=O)O)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC(N(C=N1)C)=O)O)(C)C)(C)C VIRSMLQZWDAGLJ-UWJYYQICSA-N 0.000 claims 2
- CUOLOOZOTORJDW-OFVILXPXSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC2=CN(N=C2C(=C1)C#N)C)O)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC2=CN(N=C2C(=C1)C#N)C)O)(C)C)(C)C CUOLOOZOTORJDW-OFVILXPXSA-N 0.000 claims 2
- ILANBKCNUSGLQT-URXFXBBRSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C=1C=C(C=2N(C=1)C=C(N=2)C)C#N)O)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C=1C=C(C=2N(C=1)C=C(N=2)C)C#N)O)(C)C)(C)C ILANBKCNUSGLQT-URXFXBBRSA-N 0.000 claims 2
- DPIDCRDILRBRKR-REWPJTCUSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C=1C=C(C=2N(N=1)C=C(N=2)C)C#N)O)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C=1C=C(C=2N(N=1)C=C(N=2)C)C#N)O)(C)C)(C)C DPIDCRDILRBRKR-REWPJTCUSA-N 0.000 claims 2
- QMCBJWBHFYCNGN-PXNSSMCTSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NN(C=C1)C)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NN(C=C1)C)(C)C)(C)C QMCBJWBHFYCNGN-PXNSSMCTSA-N 0.000 claims 2
- OIEOPWDKDCRVGU-REWPJTCUSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=C(C=2N(C=1)C=C(N=2)C)C(F)(F)F)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=C(C=2N(C=1)C=C(N=2)C)C(F)(F)F)(C)C)(C)C OIEOPWDKDCRVGU-REWPJTCUSA-N 0.000 claims 2
- IPXDYRBETALMJU-REWPJTCUSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=C(C=2N(N=1)C=C(N=2)C)OC)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=C(C=2N(N=1)C=C(N=2)C)OC)(C)C)(C)C IPXDYRBETALMJU-REWPJTCUSA-N 0.000 claims 2
- GNQNQQMKYGQGDD-RDPSFJRHSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)C=C(N=2)C)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)C=C(N=2)C)(C)C)(C)C GNQNQQMKYGQGDD-RDPSFJRHSA-N 0.000 claims 2
- PALHDECICFBUPD-CVDCTZTESA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)N=C(N=2)C)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)N=C(N=2)C)(C)C)(C)C PALHDECICFBUPD-CVDCTZTESA-N 0.000 claims 2
- GKKMZWHIGUOOHX-CVDCTZTESA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(N=1)C=C(N=2)C)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(N=1)C=C(N=2)C)(C)C)(C)C GKKMZWHIGUOOHX-CVDCTZTESA-N 0.000 claims 2
- ZHUYPWAWMMNBMR-AVRDEDQJSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(N=1)C=CN=2)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(N=1)C=CN=2)(C)C)(C)C ZHUYPWAWMMNBMR-AVRDEDQJSA-N 0.000 claims 2
- NONJGEBWPDUEDP-UGKGYDQZSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NC=2N(C=1)C=C(N=2)C)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NC=2N(C=1)C=C(N=2)C)(C)C)(C)C NONJGEBWPDUEDP-UGKGYDQZSA-N 0.000 claims 2
- BXVURMPIWDMWAG-AVRDEDQJSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1N=CC=2N(C=1)C=CN=2)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1N=CC=2N(C=1)C=CN=2)(C)C)(C)C BXVURMPIWDMWAG-AVRDEDQJSA-N 0.000 claims 2
- PIZWWMIEHLTZQO-YJBOKZPZSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1OC=CN=1)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1OC=CN=1)(C)C)(C)C PIZWWMIEHLTZQO-YJBOKZPZSA-N 0.000 claims 2
- BPUJYVAWMPGRRN-PXNSSMCTSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1C=NC(=C1)C)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1C=NC(=C1)C)(C)C)(C)C BPUJYVAWMPGRRN-PXNSSMCTSA-N 0.000 claims 2
- UWWFBJZCRNFLKT-LPHOPBHVSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1C=NC=C1)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1C=NC=C1)(C)C)(C)C UWWFBJZCRNFLKT-LPHOPBHVSA-N 0.000 claims 2
- OLFHWFRDWPEZMS-YJBOKZPZSA-N F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)(C)C)(C)C OLFHWFRDWPEZMS-YJBOKZPZSA-N 0.000 claims 2
- IZHIDBJWSYYKAN-HNAYVOBHSA-N F[C@H]1C(NC(C[C@@H]1NC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@@H]1NC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)(C)C)(C)C IZHIDBJWSYYKAN-HNAYVOBHSA-N 0.000 claims 2
- OXSFIWISPHERGW-DNVCBOLYSA-N F[C@H]1C(NC(C[C@H]1NC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NNC=C1)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1NC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NNC=C1)(C)C)(C)C OXSFIWISPHERGW-DNVCBOLYSA-N 0.000 claims 2
- DLSVDVRXSDKJPP-XMSQKQJNSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC(N(C=C1)C)=O)O)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC(N(C=C1)C)=O)O)(C)C)(C)C DLSVDVRXSDKJPP-XMSQKQJNSA-N 0.000 claims 2
- VIRSMLQZWDAGLJ-DYESRHJHSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC(N(C=N1)C)=O)O)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC(N(C=N1)C)=O)O)(C)C)(C)C VIRSMLQZWDAGLJ-DYESRHJHSA-N 0.000 claims 2
- CUOLOOZOTORJDW-PXDATVDWSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC2=CN(N=C2C(=C1)C#N)C)O)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C1=CC2=CN(N=C2C(=C1)C#N)C)O)(C)C)(C)C CUOLOOZOTORJDW-PXDATVDWSA-N 0.000 claims 2
- ILANBKCNUSGLQT-ZJSXRUAMSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C=1C=C(C=2N(C=1)C=C(N=2)C)C#N)O)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C=1C=C(C=2N(C=1)C=C(N=2)C)C#N)O)(C)C)(C)C ILANBKCNUSGLQT-ZJSXRUAMSA-N 0.000 claims 2
- DPIDCRDILRBRKR-NFBKMPQASA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C=1C=C(C=2N(N=1)C=C(N=2)C)C#N)O)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=C(C=C(C=N1)C=1C=C(C=2N(N=1)C=C(N=2)C)C#N)O)(C)C)(C)C DPIDCRDILRBRKR-NFBKMPQASA-N 0.000 claims 2
- QMCBJWBHFYCNGN-YLJYHZDGSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NN(C=C1)C)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NN(C=C1)C)(C)C)(C)C QMCBJWBHFYCNGN-YLJYHZDGSA-N 0.000 claims 2
- SBBKJFMLZNJVNX-OXQOHEQNSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NN2C(C=NC=C2)=N1)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C1=NN2C(C=NC=C2)=N1)(C)C)(C)C SBBKJFMLZNJVNX-OXQOHEQNSA-N 0.000 claims 2
- OIEOPWDKDCRVGU-NFBKMPQASA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=C(C=2N(C=1)C=C(N=2)C)C(F)(F)F)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=C(C=2N(C=1)C=C(N=2)C)C(F)(F)F)(C)C)(C)C OIEOPWDKDCRVGU-NFBKMPQASA-N 0.000 claims 2
- IPXDYRBETALMJU-NFBKMPQASA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=C(C=2N(N=1)C=C(N=2)C)OC)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=C(C=2N(N=1)C=C(N=2)C)OC)(C)C)(C)C IPXDYRBETALMJU-NFBKMPQASA-N 0.000 claims 2
- GNQNQQMKYGQGDD-HYBUGGRVSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)C=C(N=2)C)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)C=C(N=2)C)(C)C)(C)C GNQNQQMKYGQGDD-HYBUGGRVSA-N 0.000 claims 2
- PALHDECICFBUPD-AUSIDOKSSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)N=C(N=2)C)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)N=C(N=2)C)(C)C)(C)C PALHDECICFBUPD-AUSIDOKSSA-N 0.000 claims 2
- GKKMZWHIGUOOHX-AUSIDOKSSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(N=1)C=C(N=2)C)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(N=1)C=C(N=2)C)(C)C)(C)C GKKMZWHIGUOOHX-AUSIDOKSSA-N 0.000 claims 2
- ZHUYPWAWMMNBMR-XMSQKQJNSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(N=1)C=CN=2)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(N=1)C=CN=2)(C)C)(C)C ZHUYPWAWMMNBMR-XMSQKQJNSA-N 0.000 claims 2
- NONJGEBWPDUEDP-DENIHFKCSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NC=2N(C=1)C=C(N=2)C)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=NC=2N(C=1)C=C(N=2)C)(C)C)(C)C NONJGEBWPDUEDP-DENIHFKCSA-N 0.000 claims 2
- BXVURMPIWDMWAG-XMSQKQJNSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1N=CC=2N(C=1)C=CN=2)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1N=CC=2N(C=1)C=CN=2)(C)C)(C)C BXVURMPIWDMWAG-XMSQKQJNSA-N 0.000 claims 2
- PIZWWMIEHLTZQO-CRAIPNDOSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1OC=CN=1)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)C=1OC=CN=1)(C)C)(C)C PIZWWMIEHLTZQO-CRAIPNDOSA-N 0.000 claims 2
- BPUJYVAWMPGRRN-YLJYHZDGSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1C=NC(=C1)C)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1C=NC(=C1)C)(C)C)(C)C BPUJYVAWMPGRRN-YLJYHZDGSA-N 0.000 claims 2
- UWWFBJZCRNFLKT-VQIMIIECSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1C=NC=C1)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1C=NC=C1)(C)C)(C)C UWWFBJZCRNFLKT-VQIMIIECSA-N 0.000 claims 2
- OLFHWFRDWPEZMS-CRAIPNDOSA-N F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)(C)C)(C)C Chemical compound F[C@H]1C(NC(C[C@H]1OC1=CC=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)(C)C)(C)C OLFHWFRDWPEZMS-CRAIPNDOSA-N 0.000 claims 2
- KHMKHIIZWRVIHD-UHFFFAOYSA-N N1(C=NC=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N(C1CC(NC(C1)(C)C)(C)C)C)O Chemical compound N1(C=NC=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N(C1CC(NC(C1)(C)C)(C)C)C)O KHMKHIIZWRVIHD-UHFFFAOYSA-N 0.000 claims 2
- WCMYVSMMPWHCAM-UHFFFAOYSA-N N1(C=NC=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O Chemical compound N1(C=NC=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O WCMYVSMMPWHCAM-UHFFFAOYSA-N 0.000 claims 2
- SDRMOLGNLGUCNY-UHFFFAOYSA-N N1CCC11CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)C=C(N=2)C Chemical compound N1CCC11CN(CC1)C1=CC=C(N=N1)C1=NC=C(C=C1O)C=1C=CC=2N(C=1)C=C(N=2)C SDRMOLGNLGUCNY-UHFFFAOYSA-N 0.000 claims 2
- LCVIHPOICZRISP-UHFFFAOYSA-N N1N=CC(=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CC(NC(C1)(C)C)(C)C)O Chemical compound N1N=CC(=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)N1CC(NC(C1)(C)C)(C)C)O LCVIHPOICZRISP-UHFFFAOYSA-N 0.000 claims 2
- RWOBWFFNMXUUEJ-UHFFFAOYSA-N N=1C=CN2N=C(C=CC2=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O Chemical compound N=1C=CN2N=C(C=CC2=1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O RWOBWFFNMXUUEJ-UHFFFAOYSA-N 0.000 claims 2
- OUZVDFUBASDDQN-UHFFFAOYSA-N O1C(=NC=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O Chemical compound O1C(=NC=C1)C=1C=C(C(=NC=1)C=1N=NC(=CC=1)OC1CC(NC(C1)(C)C)(C)C)O OUZVDFUBASDDQN-UHFFFAOYSA-N 0.000 claims 2
- BNLHGAIVTUIFDA-RNHVAZJGSA-N [2H]C([2H])([2H])N1C=C(C=N1)C2=CC(=C(N=C2)C3=NN=C(C=C3)N(C)C4CC(NC5(C4)CC5)(C)C)O.Cl.Cl Chemical compound [2H]C([2H])([2H])N1C=C(C=N1)C2=CC(=C(N=C2)C3=NN=C(C=C3)N(C)C4CC(NC5(C4)CC5)(C)C)O.Cl.Cl BNLHGAIVTUIFDA-RNHVAZJGSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- BEPZJGUUEAAGDN-UHFFFAOYSA-N pyridin-3-ol dihydrochloride Chemical compound Cl.Cl.Oc1cccnc1 BEPZJGUUEAAGDN-UHFFFAOYSA-N 0.000 claims 2
- SOJWFFJJHYFRAV-FIJHWNBTSA-N 2-[3-[[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino]-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)pyridin-3-ol trihydrochloride Chemical compound CC1(C[C@H]([C@H](C(N1)(C)C)F)NC2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.Cl.Cl.Cl SOJWFFJJHYFRAV-FIJHWNBTSA-N 0.000 claims 1
- OMQHXLCATZKFCT-ITFXPAGMSA-N 2-[3-[[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino]-1,2,4-triazin-6-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]pyridin-3-ol Chemical compound F[C@H]1C(NC(C[C@H]1NC=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H])(C)C)(C)C OMQHXLCATZKFCT-ITFXPAGMSA-N 0.000 claims 1
- SOJWFFJJHYFRAV-JQUZKBDFSA-N 2-[3-[[(3S,4S)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl]amino]-1,2,4-triazin-6-yl]-5-(1H-pyrazol-4-yl)pyridin-3-ol trihydrochloride Chemical compound CC1(C[C@@H]([C@@H](C(N1)(C)C)F)NC2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.Cl.Cl.Cl SOJWFFJJHYFRAV-JQUZKBDFSA-N 0.000 claims 1
- FZIPBIZKNQKLEM-VPYROQPTSA-N 2-[3-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,2,4-triazin-6-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]pyridin-3-ol Chemical compound C(N1N=CC(=C1)C=1C=C(C(=NC=1)C1=CN=C(N=N1)N(C1CC(NC(C1)(C)C)(C)C)C)O)([2H])([2H])[2H] FZIPBIZKNQKLEM-VPYROQPTSA-N 0.000 claims 1
- PZNKFJASJZVUPT-GKOSEXJESA-N C(C)(C)(C)NC1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H] Chemical compound C(C)(C)(C)NC1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H] PZNKFJASJZVUPT-GKOSEXJESA-N 0.000 claims 1
- YVRSWWILTOCOAJ-UHFFFAOYSA-N C(C)(C)(C)NC1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NNC=1 Chemical compound C(C)(C)(C)NC1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NNC=1 YVRSWWILTOCOAJ-UHFFFAOYSA-N 0.000 claims 1
- HSOWUYWIFSRTQQ-UHFFFAOYSA-N C(C)(C)(C)NC1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)N1N=CC=N1 Chemical compound C(C)(C)(C)NC1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)N1N=CC=N1 HSOWUYWIFSRTQQ-UHFFFAOYSA-N 0.000 claims 1
- HEFQTNFGPZFGCR-LBPRGKRZSA-N C(C)(C)(C)N[C@@H]1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C(=NNC=1)F Chemical compound C(C)(C)(C)N[C@@H]1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C(=NNC=1)F HEFQTNFGPZFGCR-LBPRGKRZSA-N 0.000 claims 1
- CWHWKSRQBOWGGG-LJQANCHMSA-N C(C)(C)(C)N[C@H]1CN(CC1)C=1N=NC(=CN=1)C1=C(C=C(C=N1)C=1C=C(C=2N(C=1)C=C(N=2)C)C#N)O Chemical compound C(C)(C)(C)N[C@H]1CN(CC1)C=1N=NC(=CN=1)C1=C(C=C(C=N1)C=1C=C(C=2N(C=1)C=C(N=2)C)C#N)O CWHWKSRQBOWGGG-LJQANCHMSA-N 0.000 claims 1
- XXWWIGJEYRWJLV-GOSISDBHSA-N C(C)(C)(C)N[C@H]1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)OC)C Chemical compound C(C)(C)(C)N[C@H]1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)OC)C XXWWIGJEYRWJLV-GOSISDBHSA-N 0.000 claims 1
- PNRVTTIWUSTTSQ-HXUWFJFHSA-N C(C)(C)(C)N[C@H]1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=C(C=2N(C=1)C=C(N=2)C)CC Chemical compound C(C)(C)(C)N[C@H]1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=C(C=2N(C=1)C=C(N=2)C)CC PNRVTTIWUSTTSQ-HXUWFJFHSA-N 0.000 claims 1
- MAMDPIHLJULMKP-QGZVFWFLSA-N C(C)(C)(C)N[C@H]1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=C(C=2N(N=1)C=C(N=2)C)C Chemical compound C(C)(C)(C)N[C@H]1CN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=C(C=2N(N=1)C=C(N=2)C)C MAMDPIHLJULMKP-QGZVFWFLSA-N 0.000 claims 1
- FISABUPLTOSZLK-LJQANCHMSA-N C1(CC1)[C@H]1CN(CCN1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C Chemical compound C1(CC1)[C@H]1CN(CCN1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C1=CC2=CN(N=C2C(=C1)F)C FISABUPLTOSZLK-LJQANCHMSA-N 0.000 claims 1
- MHWMQOKSBOXDDD-QGZVFWFLSA-N C1(CC1)[C@H]1CN(CCN1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C1=CC=2C(N=C1)=NN(N=2)C Chemical compound C1(CC1)[C@H]1CN(CCN1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C1=CC=2C(N=C1)=NN(N=2)C MHWMQOKSBOXDDD-QGZVFWFLSA-N 0.000 claims 1
- YXYQDBKXOCJQFU-CQSZACIVSA-N C1(CC1)[C@H]1CN(CCN1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)N1N=CC=N1 Chemical compound C1(CC1)[C@H]1CN(CCN1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)N1N=CC=N1 YXYQDBKXOCJQFU-CQSZACIVSA-N 0.000 claims 1
- OIMRXZVZMRPNBV-MRXNPFEDSA-N C1(CC1)[C@H]1CN(CCN1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)NC1=NC=C(N=C1)C Chemical compound C1(CC1)[C@H]1CN(CCN1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)NC1=NC=C(N=C1)C OIMRXZVZMRPNBV-MRXNPFEDSA-N 0.000 claims 1
- GDTVXESEZGCXCZ-UHFFFAOYSA-N CC(C)(C)NC1CCN(C1)C2=NC=C(N=N2)C3=C(C=C(C=N3)N4N=CC=N4)O.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O Chemical compound CC(C)(C)NC1CCN(C1)C2=NC=C(N=N2)C3=C(C=C(C=N3)N4N=CC=N4)O.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O GDTVXESEZGCXCZ-UHFFFAOYSA-N 0.000 claims 1
- NTOXJDPATFMGBW-GMUIIQOCSA-N CC(C)(C)N[C@@H]1CCN(C1)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)OC)C)O.Cl Chemical compound CC(C)(C)N[C@@H]1CCN(C1)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)OC)C)O.Cl NTOXJDPATFMGBW-GMUIIQOCSA-N 0.000 claims 1
- XPNRJBVHQMXLCD-YDALLXLXSA-N CC(C)(C)N[C@H]1CCN(C1)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=C(NN=C4)F)O.Cl Chemical compound CC(C)(C)N[C@H]1CCN(C1)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=C(NN=C4)F)O.Cl XPNRJBVHQMXLCD-YDALLXLXSA-N 0.000 claims 1
- VBANRAPLARCCCX-FSRHSHDFSA-N CC(C)[C@H]1CN(CCN1)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl Chemical compound CC(C)[C@H]1CN(CCN1)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CC5=CN(N=C5C(=C4)F)C)O.Cl VBANRAPLARCCCX-FSRHSHDFSA-N 0.000 claims 1
- PYBFVDSSKHKUEF-PFEQFJNWSA-N CC(C)[C@H]1CN(CCN1)C2=NC=C(N=N2)C3=C(C=C(C=N3)N4N=CC=N4)O.Cl Chemical compound CC(C)[C@H]1CN(CCN1)C2=NC=C(N=N2)C3=C(C=C(C=N3)N4N=CC=N4)O.Cl PYBFVDSSKHKUEF-PFEQFJNWSA-N 0.000 claims 1
- MESIFGPVCAIRCJ-CQSZACIVSA-N CC(C)[C@H]1CN(CCN1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)N1N=CC=N1 Chemical compound CC(C)[C@H]1CN(CCN1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)N1N=CC=N1 MESIFGPVCAIRCJ-CQSZACIVSA-N 0.000 claims 1
- VULUMYXBVCNNIB-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N(C)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=C(NN=C4)F)O)C.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O Chemical compound CC1(CC(CC(N1)(C)C)N(C)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=C(NN=C4)F)O)C.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O VULUMYXBVCNNIB-UHFFFAOYSA-N 0.000 claims 1
- YNCQBXTWZCXCMQ-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N(C)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.C(=O)(C(F)(F)F)O Chemical compound CC1(CC(CC(N1)(C)C)N(C)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.C(=O)(C(F)(F)F)O YNCQBXTWZCXCMQ-UHFFFAOYSA-N 0.000 claims 1
- WNFGKOIFTZXOFK-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N(C)C2=NC=C(N=N2)C3=C(C=C(C=N3)N4N=CC=N4)O)C.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O Chemical compound CC1(CC(CC(N1)(C)C)N(C)C2=NC=C(N=N2)C3=C(C=C(C=N3)N4N=CC=N4)O)C.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O WNFGKOIFTZXOFK-UHFFFAOYSA-N 0.000 claims 1
- AZJICKVUZWEGSC-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)OC2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.C(=O)(C(F)(F)F)O Chemical compound CC1(CC(CC(N1)(C)C)OC2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CNN=C4)O)C.C(=O)(C(F)(F)F)O AZJICKVUZWEGSC-UHFFFAOYSA-N 0.000 claims 1
- SMHURZAZIBVBCX-UHFFFAOYSA-N CC1(NC(CC(C1)NC1=CN=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)(C)C)C Chemical compound CC1(NC(CC(C1)NC1=CN=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)(C)C)C SMHURZAZIBVBCX-UHFFFAOYSA-N 0.000 claims 1
- QIZHSXGFEFYZEG-UHFFFAOYSA-N CC1=CC(=CN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CCN(CC5)C)O.Cl Chemical compound CC1=CC(=CN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CCN(CC5)C)O.Cl QIZHSXGFEFYZEG-UHFFFAOYSA-N 0.000 claims 1
- SLTAYIBWNKEUTL-UNTBIKODSA-N CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CC[C@H](C5)NC(C)(C)C)O.Cl Chemical compound CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CC[C@H](C5)NC(C)(C)C)O.Cl SLTAYIBWNKEUTL-UNTBIKODSA-N 0.000 claims 1
- HPCBZBOEPCFFAB-FSRHSHDFSA-N CC1=CN2C=C(C=C(C2=N1)C#N)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CC[C@H](C5)NC(C)(C)C)O.Cl Chemical compound CC1=CN2C=C(C=C(C2=N1)C#N)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CC[C@H](C5)NC(C)(C)C)O.Cl HPCBZBOEPCFFAB-FSRHSHDFSA-N 0.000 claims 1
- ZOXYAYUKSHICFA-UHFFFAOYSA-N CC1=CN2C=C(C=C(C2=N1)F)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CCN(CC5)C)O.Cl Chemical compound CC1=CN2C=C(C=C(C2=N1)F)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CCN(CC5)C)O.Cl ZOXYAYUKSHICFA-UHFFFAOYSA-N 0.000 claims 1
- SRLTVWRQYPEAJU-GGMCWBHBSA-N CC1=CN=C(C=N1)NC2=CC(=C(N=C2)C3=CN=C(N=N3)N4CCN[C@H](C4)C(C)C)O.Cl.Cl Chemical compound CC1=CN=C(C=N1)NC2=CC(=C(N=C2)C3=CN=C(N=N3)N4CCN[C@H](C4)C(C)C)O.Cl.Cl SRLTVWRQYPEAJU-GGMCWBHBSA-N 0.000 claims 1
- MMEQCTXELXDEQI-PKLMIRHRSA-N CC1=CN=C(C=N1)NC2=CC(=C(N=C2)C3=CN=C(N=N3)N4CCN[C@H](C4)C5CC5)O.Cl Chemical compound CC1=CN=C(C=N1)NC2=CC(=C(N=C2)C3=CN=C(N=N3)N4CCN[C@H](C4)C5CC5)O.Cl MMEQCTXELXDEQI-PKLMIRHRSA-N 0.000 claims 1
- IAYQTGOVQTYTOK-UHFFFAOYSA-N CC=1N=C2N(C=C(C=C2C)C=2C=C(C(=NC=2)C2=CN=C(N=N2)N2CCN(CC2)C)O)C=1 Chemical compound CC=1N=C2N(C=C(C=C2C)C=2C=C(C(=NC=2)C2=CN=C(N=N2)N2CCN(CC2)C)O)C=1 IAYQTGOVQTYTOK-UHFFFAOYSA-N 0.000 claims 1
- FNCJJUVZGCQPNB-MRXNPFEDSA-N CC=1N=CC(=NC=1)NC=1C=C(C(=NC=1)C1=CN=C(N=N1)N1C[C@@H](NCC1)C(C)C)O Chemical compound CC=1N=CC(=NC=1)NC=1C=C(C(=NC=1)C1=CN=C(N=N1)N1C[C@@H](NCC1)C(C)C)O FNCJJUVZGCQPNB-MRXNPFEDSA-N 0.000 claims 1
- BWQVOQZNNPBAOH-VEIFNGETSA-N CCC1=CC(=CN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CC[C@H](C5)NC(C)(C)C)O.Cl Chemical compound CCC1=CC(=CN2C1=NC(=C2)C)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CC[C@H](C5)NC(C)(C)C)O.Cl BWQVOQZNNPBAOH-VEIFNGETSA-N 0.000 claims 1
- UFYAVVZXFDJKLZ-UHFFFAOYSA-N CN(C1=CN=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)C1CC(NC(C1)(C)C)(C)C Chemical compound CN(C1=CN=C(N=N1)C1=NC=C(C=C1O)C=1C=NNC=1)C1CC(NC(C1)(C)C)(C)C UFYAVVZXFDJKLZ-UHFFFAOYSA-N 0.000 claims 1
- JNKWNRRYSVAFNP-UHFFFAOYSA-N CN(C1=CN=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)C1CC(NC(C1)(C)C)(C)C Chemical compound CN(C1=CN=C(N=N1)C1=NC=C(C=C1O)N1N=CC=N1)C1CC(NC(C1)(C)C)(C)C JNKWNRRYSVAFNP-UHFFFAOYSA-N 0.000 claims 1
- CQWNXMPKBDVNDU-UHFFFAOYSA-N CN(C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NNC=1)C1CC(NC(C1)(C)C)(C)C Chemical compound CN(C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NNC=1)C1CC(NC(C1)(C)C)(C)C CQWNXMPKBDVNDU-UHFFFAOYSA-N 0.000 claims 1
- NXCRUMWAWMQBEE-UHFFFAOYSA-N CN(C=1N=NC(=CN=1)C1=NC=C(C=C1O)N1N=CC=N1)C1CC(NC(C1)(C)C)(C)C Chemical compound CN(C=1N=NC(=CN=1)C1=NC=C(C=C1O)N1N=CC=N1)C1CC(NC(C1)(C)C)(C)C NXCRUMWAWMQBEE-UHFFFAOYSA-N 0.000 claims 1
- WWIQQEZDJKOGPX-FSRHSHDFSA-N CN1C=C2C=C(C=C(C2=N1)F)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CCN[C@H](C5)C6CC6)O.Cl Chemical compound CN1C=C2C=C(C=C(C2=N1)F)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CCN[C@H](C5)C6CC6)O.Cl WWIQQEZDJKOGPX-FSRHSHDFSA-N 0.000 claims 1
- KTUZYVLWPCKANX-UHFFFAOYSA-N CN1CCN(CC1)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl Chemical compound CN1CCN(CC1)C2=NC=C(N=N2)C3=C(C=C(C=N3)C4=CNN=C4)O.Cl KTUZYVLWPCKANX-UHFFFAOYSA-N 0.000 claims 1
- JFFKLPYONSTGQJ-UHFFFAOYSA-N CN1CCN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NNC=1 Chemical compound CN1CCN(CC1)C=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NNC=1 JFFKLPYONSTGQJ-UHFFFAOYSA-N 0.000 claims 1
- PPKUQOUVLOQYGS-UNTBIKODSA-N CN1N=C2C=C(C=NC2=N1)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CCN[C@H](C5)C6CC6)O.C(=O)(C(F)(F)F)O Chemical compound CN1N=C2C=C(C=NC2=N1)C3=CC(=C(N=C3)C4=CN=C(N=N4)N5CCN[C@H](C5)C6CC6)O.C(=O)(C(F)(F)F)O PPKUQOUVLOQYGS-UNTBIKODSA-N 0.000 claims 1
- NTQHFMGFUTTWLA-UHFFFAOYSA-N COC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C1=CN=C(N=N1)N1CCN(CC1)C)O Chemical compound COC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C1=CN=C(N=N1)N1CCN(CC1)C)O NTQHFMGFUTTWLA-UHFFFAOYSA-N 0.000 claims 1
- ZOVFFNSLQCBUSB-UHFFFAOYSA-N FC1=C(C=NN1)C=1C=C(C(=NC=1)C1=CN=C(N=N1)N(C1CC(NC(C1)(C)C)(C)C)C)O Chemical compound FC1=C(C=NN1)C=1C=C(C(=NC=1)C1=CN=C(N=N1)N(C1CC(NC(C1)(C)C)(C)C)C)O ZOVFFNSLQCBUSB-UHFFFAOYSA-N 0.000 claims 1
- JSPUREQPMOYERR-LJQANCHMSA-N FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C1=CN=C(N=N1)N1C[C@@H](NCC1)C(C)C)O Chemical compound FC1=CC(=CC2=CN(N=C12)C)C=1C=C(C(=NC=1)C1=CN=C(N=N1)N1C[C@@H](NCC1)C(C)C)O JSPUREQPMOYERR-LJQANCHMSA-N 0.000 claims 1
- SFANOCTXGZBQGC-UHFFFAOYSA-N FC=1C=2N(C=C(C=1)C=1C=C(C(=NC=1)C1=CN=C(N=N1)N1CCN(CC1)C)O)C=C(N=2)C Chemical compound FC=1C=2N(C=C(C=1)C=1C=C(C(=NC=1)C1=CN=C(N=N1)N1CCN(CC1)C)O)C=C(N=2)C SFANOCTXGZBQGC-UHFFFAOYSA-N 0.000 claims 1
- OMQHXLCATZKFCT-PPTCOAGHSA-N F[C@@H]1C(NC(C[C@@H]1NC=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H])(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1NC=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NN(C=1)C([2H])([2H])[2H])(C)C)(C)C OMQHXLCATZKFCT-PPTCOAGHSA-N 0.000 claims 1
- GHISXFMKCRMQKA-GUYCJALGSA-N F[C@@H]1C(NC(C[C@@H]1NC=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NNC=1)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1NC=1N=NC(=CN=1)C1=NC=C(C=C1O)C=1C=NNC=1)(C)C)(C)C GHISXFMKCRMQKA-GUYCJALGSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- SUBWTVVTSSCVDC-UHFFFAOYSA-N N1N=CC(=C1)C=1C=C(C(=NC=1)C1=CN=C(N=N1)OC1CC(NC(C1)(C)C)(C)C)O Chemical compound N1N=CC(=C1)C=1C=C(C(=NC=1)C1=CN=C(N=N1)OC1CC(NC(C1)(C)C)(C)C)O SUBWTVVTSSCVDC-UHFFFAOYSA-N 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 81
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 80
- 125000003373 pyrazinyl group Chemical group 0.000 description 50
- 125000005983 2,5-diazabicyclo[2.2.1]heptan-2-yl group Chemical group 0.000 description 42
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 41
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 37
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 29
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 28
- BHFXPKPIPBNKFI-UHFFFAOYSA-N 2,3,4,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-6-one Chemical compound C1NCCN2C(=O)CCC21 BHFXPKPIPBNKFI-UHFFFAOYSA-N 0.000 description 28
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 28
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 28
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 28
- 125000002393 azetidinyl group Chemical group 0.000 description 28
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 28
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 28
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 28
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 28
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 25
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 22
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 22
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 22
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 22
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 22
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 22
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 22
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 22
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 22
- 125000001041 indolyl group Chemical group 0.000 description 22
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 22
- 125000000714 pyrimidinyl group Chemical group 0.000 description 22
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 22
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 22
- 125000001544 thienyl group Chemical group 0.000 description 22
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 description 21
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 21
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 21
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 21
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 21
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 21
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 18
- 125000004613 furo[2,3-c]pyridinyl group Chemical group O1C(=CC=2C1=CN=CC2)* 0.000 description 15
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 13
- 125000001506 1,2,3-triazol-5-yl group Chemical group [H]N1N=NC([H])=C1[*] 0.000 description 13
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 13
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 description 13
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 13
- 125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 description 13
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 13
- 125000004317 1,3,5-triazin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=N1 0.000 description 13
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 13
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 13
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 13
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 13
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 13
- 125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 description 13
- 125000004534 benzothien-2-yl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 13
- 125000004197 benzothien-3-yl group Chemical group [H]C1=C(*)C2=C([H])C([H])=C([H])C([H])=C2S1 0.000 description 13
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 13
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 13
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 13
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 13
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 13
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 13
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 13
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 13
- 125000004227 1,3-benzoxazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)OC2=C1[H] 0.000 description 12
- 125000001153 fluoro group Chemical group F* 0.000 description 12
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 12
- 125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
- 125000002346 iodo group Chemical group I* 0.000 description 6
- 125000004431 deuterium atom Chemical group 0.000 description 5
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962846896P | 2019-05-13 | 2019-05-13 | |
| US62/846,896 | 2019-05-13 | ||
| PCT/US2020/032446 WO2020231977A1 (en) | 2019-05-13 | 2020-05-12 | Compounds for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020277027A1 true AU2020277027A1 (en) | 2021-12-09 |
Family
ID=70919171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020277027A Abandoned AU2020277027A1 (en) | 2019-05-13 | 2020-05-12 | Compounds for treating huntington's disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12577226B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4219466A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7649257B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220022114A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114245794B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020277027A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021022624A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3139821A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL287945B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021013854A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202112504YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020231977A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| MX2022012575A (es) * | 2020-04-09 | 2023-01-24 | Ptc Therapeutics Inc | Compuestos para usarse para tratar la enfermedad de huntington. |
| WO2021231571A1 (en) | 2020-05-13 | 2021-11-18 | Chdi Foundation, Inc. | Htt modulators for treating huntington's disease |
| WO2022230912A1 (ja) | 2021-04-28 | 2022-11-03 | アステラス製薬株式会社 | 置換トリアジン化合物 |
| IL310992A (en) | 2021-08-25 | 2024-04-01 | Ptc Therapeutics Inc | NLRP3 inhibitors |
| WO2023034827A1 (en) * | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20250333397A1 (en) * | 2021-08-30 | 2025-10-30 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| AU2022394333A1 (en) | 2021-11-17 | 2024-06-27 | Chdi Foundation, Inc. | HTT modulators for treating Huntington’s disease |
| MX2024008548A (es) * | 2022-01-07 | 2024-07-19 | Transthera Sciences Nanjing Inc | Inhibidor del inflamosoma nlrp3 y uso del mismo. |
| CN119059962A (zh) * | 2024-09-09 | 2024-12-03 | 郑州药领医药科技有限公司 | 一种n保护的2,2-二甲基哌啶-4-酮的制备方法 |
Family Cites Families (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (cg-RX-API-DMAC7.html) | 1963-04-04 | 1900-01-01 | ||
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| GB1383409A (en) | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| JPS5852307A (ja) | 1981-09-22 | 1983-03-28 | Hitachi Chem Co Ltd | 水分散樹脂組成物 |
| FR2567518B1 (fr) | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US4902695A (en) | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| US5599816A (en) | 1990-05-02 | 1997-02-04 | Abbott Laboratories | Quinolizinone type compounds |
| EP0640083A1 (en) | 1992-05-13 | 1995-03-01 | E.I. Du Pont De Nemours And Company | Substituted pyrido 1,2-a]pyrimidinone derivatives as fungicides |
| ATE368107T1 (de) | 1993-05-11 | 2007-08-15 | Univ North Carolina | Antisense oligonukleotide die anomales splicing verhindern und deren verwendung |
| KR19990022524A (ko) | 1995-06-06 | 1999-03-25 | 웨인스톡 스티븐 에프. | 퀴놀리지논형화합물 |
| US5916916A (en) | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| CA2269561C (en) | 1998-04-22 | 2007-06-05 | Dainippon Ink And Chemicals, Inc. | Naphthalene derivative and liquid crystal composition comprising the same |
| HK1040076A1 (zh) | 1998-09-21 | 2002-05-24 | 希雷生物化学有限公司 | 作为整联蛋白抑制剂的喹嗪酮 |
| US6172216B1 (en) | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| EP1227084B1 (en) | 1999-10-28 | 2005-12-14 | Trine Pharmaceuticals, Inc. | Drug discharge pump inhibitors |
| ATE363471T1 (de) | 2000-01-24 | 2007-06-15 | Astrazeneca Ab | Durch einen morpholinrest substituierte therapeutische verbindungen |
| US20050054836A1 (en) | 2000-11-09 | 2005-03-10 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
| US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| JPWO2002087589A1 (ja) | 2001-04-26 | 2004-08-12 | 第一製薬株式会社 | 薬剤排出ポンプ阻害薬 |
| ATE466581T1 (de) | 2001-12-07 | 2010-05-15 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| EP1542667B1 (en) | 2002-07-24 | 2012-03-07 | PTC Therapeutics, Inc. | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| US7423133B2 (en) | 2002-08-23 | 2008-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent glycosides and methods for their use |
| DE60311853T2 (de) | 2002-09-30 | 2007-06-21 | Neurosearch A/S | Neue 1,4-diazabicycloalkanderivate, deren herstellung und verwendung |
| CA2765093A1 (en) | 2002-11-12 | 2004-05-27 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
| US20070078144A1 (en) | 2003-01-29 | 2007-04-05 | Stockwell Brent R | Agents for treating neurodegenerative diseases |
| US20040224952A1 (en) | 2003-05-07 | 2004-11-11 | Cowart Marlon D. | Fused bicyclic-substituted amines as histamine-3 receptor ligands |
| ES2339862T3 (es) | 2003-06-20 | 2010-05-26 | Novartis Vaccines And Diagnostics, Inc. | Compuestos de piridino 1,2-a-pirimidin-4-ona como agentes anticancerosos. |
| GB0315494D0 (en) | 2003-07-02 | 2003-08-06 | Biofocus Plc | Compounds which bind to the active site of protein kinase enzymes |
| BRPI0413234A (pt) | 2003-08-01 | 2006-10-03 | Genelabs Tech Inc | derivados de imidazola bicìclica contra flaviviridae |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| US7309699B2 (en) | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
| US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050137203A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| CA2551178C (en) | 2003-12-24 | 2012-11-06 | Biota Scientific Management Pty Ltd | Polycyclic agents for the treatment of respiratory syncytial virus infections |
| SE0400184D0 (sv) | 2004-01-30 | 2004-01-30 | Fyrkloevern Scandinavia Ab | New therapeutical use |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| CN1964717A (zh) | 2004-04-08 | 2007-05-16 | 神经能质公司 | 经取代∴啉-4-基胺 |
| ZA200609267B (en) | 2004-04-08 | 2009-02-25 | Targegen Inc | Benzotriazine inhibitors of kinases |
| WO2005105801A1 (en) | 2004-05-04 | 2005-11-10 | Warner-Lambert Company Llc | Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents |
| US7399767B2 (en) | 2005-01-21 | 2008-07-15 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP2006219453A (ja) | 2005-02-14 | 2006-08-24 | Tokyo Univ Of Pharmacy & Life Science | キノリン環を母核とする金属識別型二波長性蛍光分子 |
| US7563601B1 (en) | 2005-06-01 | 2009-07-21 | City Of Hope | Artificial riboswitch for controlling pre-mRNA splicing |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| CN103110635A (zh) | 2005-07-04 | 2013-05-22 | 海波因特制药有限责任公司 | 组胺h3受体拮抗剂 |
| US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| US7576110B2 (en) | 2005-09-22 | 2009-08-18 | Abbott Laboratories | Benzothiazole cyclobutyl amine derivatives |
| US8258109B2 (en) | 2005-10-20 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of LMNA expression |
| WO2007056580A2 (en) | 2005-11-08 | 2007-05-18 | Pharmadyn, Inc. | Methods and compositions for treating diseases associated with pathogenic proteins |
| WO2007058894A2 (en) | 2005-11-10 | 2007-05-24 | The University Of North Carolina At Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| CA2632642A1 (en) | 2005-12-06 | 2007-06-14 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| JP2009520700A (ja) | 2005-12-21 | 2009-05-28 | ペインセプター ファーマ コーポレーション | 依存性イオンチャネルを調節するための組成物および方法 |
| EP2422819B1 (en) | 2006-01-26 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
| EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| NZ570524A (en) | 2006-03-28 | 2011-08-26 | High Point Pharmaceuticals Llc | Benzothiazoles having histamine H3 receptor activity |
| WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| US20080247964A1 (en) | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| WO2007133756A2 (en) | 2006-05-15 | 2007-11-22 | Neurogen Corporation | Crf1 receptor ligands comprising heteroaryl fused bicycles |
| JP2009537599A (ja) | 2006-05-23 | 2009-10-29 | ノイロサーチ アクティーゼルスカブ | 新規8,10−ジアザ−ビシクロ[4.3.1]デカン誘導体及びそれらの医学的使用 |
| EP2079724B1 (en) | 2006-07-20 | 2010-05-26 | Amgen Inc. | Substituted pyridone compounds and methods of use |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| US7994181B2 (en) | 2006-08-03 | 2011-08-09 | Rottapharm S.P.A. | 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| EP2079734A1 (en) | 2006-10-25 | 2009-07-22 | NeuroSearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| AR064517A1 (es) | 2006-12-22 | 2009-04-08 | Avexa Ltd | Pirimidinionas biciclicas y sus usos |
| US20080171792A1 (en) | 2006-12-28 | 2008-07-17 | Jobdevairakkam Christopher New | Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders |
| FR2914188B1 (fr) | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
| EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
| DK2193133T3 (en) | 2007-09-27 | 2015-10-05 | Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii | IMIDAZOLOTHIADIAZOLES USED AS PROTEINKINASE INHIBITORS |
| CA2700841A1 (en) | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US8153813B2 (en) | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| US20090258907A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | Compounds useful as inhibitors of rock kinases |
| WO2009131958A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
| US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| BRPI0822462A2 (pt) | 2008-06-20 | 2015-10-13 | Rottapharm Spa | derivados de 6-1h-imidazo-quinazolina e de quinolinas, novos inibidores de mao e ligantes a receptor de imidazolina. |
| EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| US8318732B2 (en) | 2008-07-02 | 2012-11-27 | Avexa Limited | Compounds having antiviral properties |
| WO2010019236A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc | Methods for treating spinal muscular atrophy |
| WO2010024903A1 (en) | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
| EP2350067A2 (en) | 2008-10-16 | 2011-08-03 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2010071819A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| AU2010214101A1 (en) | 2009-02-11 | 2011-09-01 | Sunovion Pharmaceuticals Inc. | Histamine H3 inverse agonists and antagonists and methods of use thereof |
| FR2945289A1 (fr) | 2009-05-11 | 2010-11-12 | Sanofi Aventis | Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique |
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| WO2010145208A1 (en) | 2009-06-19 | 2010-12-23 | Abbott Laboratories | Diazahomoadamantane derivatives and methods of use thereof |
| EP3626823A1 (en) | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| US20150018301A1 (en) | 2009-11-06 | 2015-01-15 | The Johns Hopkins University | LRRK-2-Mediated Neuronal Toxicity |
| EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| KR20130088002A (ko) | 2010-01-13 | 2013-08-07 | 재단법인 한국파스퇴르연구소 | 항-감염성 피리도(1,2-a)피리미딘 |
| EP2536738A4 (en) | 2010-02-08 | 2014-09-17 | Isis Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OR SUFFERING IN CONNECTION WITH REPEAT EXTENSIONS |
| JP6018506B2 (ja) | 2010-02-08 | 2016-11-02 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 対立遺伝子多様体の選択的低減 |
| ES2733708T3 (es) | 2010-02-08 | 2019-12-02 | Ionis Pharmaceuticals Inc | Reducción selectiva de variantes alélicas |
| CN102971311B (zh) | 2010-05-06 | 2015-07-08 | 百时美施贵宝公司 | 作为gpr119调节剂的二环杂芳基化合物 |
| CA2800509A1 (en) | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| ES2756326T3 (es) | 2010-07-19 | 2020-04-27 | Ionis Pharmaceuticals Inc | Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK) |
| WO2012019106A2 (en) | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| CN102617548A (zh) | 2011-01-31 | 2012-08-01 | 北京赛林泰医药技术有限公司 | 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用 |
| WO2012104823A2 (en) | 2011-02-04 | 2012-08-09 | Novartis Ag | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases |
| CN106278999B (zh) | 2011-02-07 | 2019-10-25 | 比奥根Ma公司 | S1p调节剂 |
| US10017764B2 (en) | 2011-02-08 | 2018-07-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| US9447075B2 (en) | 2011-08-02 | 2016-09-20 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as EAAT2 activators |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| US20140303235A1 (en) | 2011-08-11 | 2014-10-09 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
| US20130046093A1 (en) | 2011-08-18 | 2013-02-21 | Korea Institute Of Science And Technology | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same |
| EP2751269B1 (en) | 2011-08-29 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| US9662314B2 (en) | 2011-10-21 | 2017-05-30 | Tufts Medical Center, Inc. | Compounds and methods for the treatment of muscular disease, and related screening methods |
| GB201119538D0 (en) | 2011-11-10 | 2011-12-21 | Viral Ltd | Pharmaceutical compounds |
| CA2856334A1 (en) | 2011-11-28 | 2013-06-06 | Christina Hebach | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP3406252B1 (en) | 2012-02-10 | 2020-05-13 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US9371336B2 (en) | 2012-03-01 | 2016-06-21 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2828247B1 (en) | 2012-03-23 | 2019-01-16 | PTC Therapeutics, Inc. | 4h-chromen-4-one derivatives for treating spinal muscular atrophy |
| US9199946B2 (en) | 2012-04-03 | 2015-12-01 | Bristol-Myers Squibb Company | Pyrimidinone carboxamide inhibitors of endothelial lipase |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| US9212209B2 (en) | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| EP2906255B1 (en) | 2012-10-12 | 2023-02-22 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| EP4086347A3 (en) | 2012-10-12 | 2023-01-11 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| CA2889494C (en) | 2012-10-25 | 2018-12-18 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| JP6255711B2 (ja) | 2012-11-01 | 2018-01-10 | 株式会社リコー | エレクトロクロミック化合物、エレクトロクロミック組成物及び表示素子 |
| US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
| EP2951304B1 (en) | 2013-02-04 | 2020-07-08 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| CA2903903C (en) | 2013-03-05 | 2021-05-04 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer |
| JP2016518421A (ja) | 2013-05-14 | 2016-06-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール |
| CA2913785C (en) | 2013-06-25 | 2021-08-31 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| CN105636953B (zh) | 2013-07-31 | 2018-01-02 | 诺华股份有限公司 | 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途 |
| CA2915764A1 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| WO2015095449A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount rna transcripts |
| WO2015105657A1 (en) | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| WO2015095446A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| AR099134A1 (es) | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
| CN106103416B (zh) | 2014-03-14 | 2021-03-02 | 拉夸里亚创药株式会社 | 作为trpm8拮抗剂的氮杂螺衍生物 |
| CN106573880B (zh) | 2014-03-19 | 2019-07-30 | 阿米达斯公司 | 淀粉样蛋白靶向剂及其使用方法 |
| AU2015261046C1 (en) | 2014-05-15 | 2019-07-25 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| MX375925B (es) | 2014-06-25 | 2025-03-07 | Hoffmann La Roche | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. |
| MX381224B (es) | 2014-10-31 | 2025-03-12 | Massachusetts Gen Hospital | Potentes moduladores de gamma-secretasa. |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| CN107207526A (zh) | 2014-12-02 | 2017-09-26 | 拜耳作物科学股份公司 | 作为害虫防治剂的双环化合物 |
| AU2015370903B2 (en) | 2014-12-24 | 2021-06-17 | Uniqure Ip B.V. | RNAi induced huntingtin gene suppression |
| CA3199430A1 (en) | 2015-01-16 | 2016-07-21 | The General Hospital Corporation | Compounds for improving mrna splicing |
| EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
| GB201502567D0 (en) | 2015-02-16 | 2015-04-01 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN107635984B (zh) | 2015-03-11 | 2021-04-13 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
| GB201506933D0 (en) | 2015-04-23 | 2015-06-10 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| CN117965536A (zh) | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| WO2017023987A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| AU2016353961B2 (en) | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| AR106652A1 (es) | 2015-11-12 | 2018-02-07 | Hoffmann La Roche | Compuestos para tratar la esclerosis lateral amiotrófica |
| US10383867B2 (en) | 2015-11-28 | 2019-08-20 | Russell Dahl | Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| CA3119019C (en) * | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| EP3426653B1 (en) | 2016-03-11 | 2021-12-15 | AC Immune SA | Bicyclic compounds for diagnosis and therapy |
| US10526345B2 (en) | 2016-04-08 | 2020-01-07 | Mankind Pharma Ltd. | Compounds as GPR119 agonists |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| EP3452596A4 (en) | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| US10730868B2 (en) | 2016-07-14 | 2020-08-04 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
| US20190264267A1 (en) | 2016-07-25 | 2019-08-29 | Wave Life Sciences Ltd. | Phasing |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| US11857599B2 (en) | 2017-04-03 | 2024-01-02 | Acceleron Pharma Inc. | Compositions and methods for treating spinal muscular atrophy |
| US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| US12138263B2 (en) | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| CN117263942A (zh) | 2018-03-21 | 2023-12-22 | 传达治疗有限公司 | Shp2磷酸酶抑制剂及其使用方法 |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| JP2022525417A (ja) | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| WO2021007378A1 (en) | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
| TW202131920A (zh) | 2019-11-01 | 2021-09-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| AU2021228284A1 (en) | 2020-02-28 | 2022-09-29 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| MX2022012575A (es) * | 2020-04-09 | 2023-01-24 | Ptc Therapeutics Inc | Compuestos para usarse para tratar la enfermedad de huntington. |
| EP4244362A1 (en) | 2020-11-12 | 2023-09-20 | PTC Therapeutics, Inc. | Novel rna transcript |
| CN118159539A (zh) | 2021-07-30 | 2024-06-07 | Ptc医疗公司 | 用于治疗亨廷顿氏病的杂芳基化合物 |
| CA3249778A1 (en) | 2022-06-15 | 2023-12-21 | Ptc Therapeutics, Inc. | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE |
-
2020
- 2020-05-12 CA CA3139821A patent/CA3139821A1/en active Pending
- 2020-05-12 KR KR1020217036718A patent/KR20220022114A/ko active Pending
- 2020-05-12 JP JP2021568200A patent/JP7649257B2/ja active Active
- 2020-05-12 US US17/610,617 patent/US12577226B2/en active Active
- 2020-05-12 AU AU2020277027A patent/AU2020277027A1/en not_active Abandoned
- 2020-05-12 MX MX2021013854A patent/MX2021013854A/es unknown
- 2020-05-12 EP EP23162466.9A patent/EP4219466A1/en active Pending
- 2020-05-12 BR BR112021022624A patent/BR112021022624A2/pt not_active Application Discontinuation
- 2020-05-12 IL IL287945A patent/IL287945B2/en unknown
- 2020-05-12 CN CN202080050837.0A patent/CN114245794B/zh active Active
- 2020-05-12 WO PCT/US2020/032446 patent/WO2020231977A1/en not_active Ceased
- 2020-05-12 EP EP20729481.0A patent/EP3969446B1/en active Active
- 2020-05-12 SG SG11202112504YA patent/SG11202112504YA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114245794B (zh) | 2024-09-13 |
| WO2020231977A1 (en) | 2020-11-19 |
| SG11202112504YA (en) | 2021-12-30 |
| JP2022533120A (ja) | 2022-07-21 |
| CA3139821A1 (en) | 2020-11-19 |
| JP7649257B2 (ja) | 2025-03-19 |
| IL287945B1 (en) | 2025-11-01 |
| KR20220022114A (ko) | 2022-02-24 |
| US20220204478A1 (en) | 2022-06-30 |
| BR112021022624A2 (pt) | 2022-01-04 |
| US12577226B2 (en) | 2026-03-17 |
| EP4219466A1 (en) | 2023-08-02 |
| EP3969446A1 (en) | 2022-03-23 |
| CN114245794A (zh) | 2022-03-25 |
| MX2021013854A (es) | 2022-03-22 |
| IL287945A (en) | 2022-01-01 |
| IL287945B2 (en) | 2026-03-01 |
| EP3969446B1 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7649257B2 (ja) | ハンチントン病を処置するための化合物 | |
| JP7399869B2 (ja) | ハンチントン病を処置するための化合物 | |
| JP7421507B2 (ja) | ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物 | |
| US11685746B2 (en) | Heteroaryl compounds for treating Huntington's disease | |
| WO2021207453A1 (en) | Compounds for treating huntington's disease | |
| HK40116823A (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| US20240132509A1 (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| EA046152B1 (ru) | Соединения для лечения болезни гентингтона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ SYDORENKO, NADIYA; ALAM, RAUFUL; AMEDZO, LUKIANA; ARNOLD, MICHAEL A.; BABU, SURESH; BHATTACHARYYA, ANURADHA; KARP, GARY MITCHELL; KENTON, NATHANIEL T.; LUONG, TOM TUAN; MAZZOTTI, ANTHONY R.; MOON, YOUNG-CHOON; MORRILL, CHRISTIE; MSZAR, NICHOLAS WALTER; NARASIMHAN, JANA; PATEL, JIGAR S.; REN, HONGYU; TURPOFF, ANTHONY; WANG, GANG; WOLL, MATTHEW G.; ZHANG, NANJING AND ZHANG, XIAOYAN |
|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |